EP0756461B1 - Tobacco products, or substances similar to such products, containing natural substances with anti-oxidant properties, and process for producing the same - Google Patents
Tobacco products, or substances similar to such products, containing natural substances with anti-oxidant properties, and process for producing the same Download PDFInfo
- Publication number
- EP0756461B1 EP0756461B1 EP95917934A EP95917934A EP0756461B1 EP 0756461 B1 EP0756461 B1 EP 0756461B1 EP 95917934 A EP95917934 A EP 95917934A EP 95917934 A EP95917934 A EP 95917934A EP 0756461 B1 EP0756461 B1 EP 0756461B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tobacco
- smokable
- natural substances
- filter
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000005445 natural material Substances 0.000 title claims abstract description 42
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000008569 process Effects 0.000 title claims abstract description 8
- 239000000126 substance Substances 0.000 title claims description 44
- 235000019505 tobacco product Nutrition 0.000 title description 21
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims abstract description 60
- 241000208125 Nicotiana Species 0.000 claims abstract description 57
- 239000000463 material Substances 0.000 claims abstract description 27
- 241000196324 Embryophyta Species 0.000 claims abstract description 19
- 230000002790 anti-mutagenic effect Effects 0.000 claims abstract description 11
- 229940088594 vitamin Drugs 0.000 claims abstract description 9
- 229930003231 vitamin Natural products 0.000 claims abstract description 9
- 235000013343 vitamin Nutrition 0.000 claims abstract description 9
- 239000011782 vitamin Substances 0.000 claims abstract description 9
- 239000002243 precursor Substances 0.000 claims abstract description 3
- 235000019504 cigarettes Nutrition 0.000 claims description 42
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 32
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 17
- 239000005770 Eugenol Substances 0.000 claims description 17
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 17
- 229960002217 eugenol Drugs 0.000 claims description 17
- 239000004848 polyfunctional curative Substances 0.000 claims description 14
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 claims description 12
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- 229920002301 cellulose acetate Polymers 0.000 claims description 8
- 230000000391 smoking effect Effects 0.000 claims description 8
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 7
- 235000017803 cinnamon Nutrition 0.000 claims description 7
- 229940073505 ethyl vanillin Drugs 0.000 claims description 6
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- 150000001299 aldehydes Chemical class 0.000 claims description 4
- 229940087168 alpha tocopherol Drugs 0.000 claims description 4
- 229960003471 retinol Drugs 0.000 claims description 4
- 239000011607 retinol Substances 0.000 claims description 4
- 235000020944 retinol Nutrition 0.000 claims description 4
- 229960000984 tocofersolan Drugs 0.000 claims description 4
- 235000004835 α-tocopherol Nutrition 0.000 claims description 4
- 239000002076 α-tocopherol Substances 0.000 claims description 4
- 235000008499 Canella winterana Nutrition 0.000 claims description 3
- 244000080208 Canella winterana Species 0.000 claims description 3
- 229940017545 cinnamon bark Drugs 0.000 claims description 3
- 239000011888 foil Substances 0.000 claims description 3
- 244000178870 Lavandula angustifolia Species 0.000 claims description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 2
- 235000014749 Mentha crispa Nutrition 0.000 claims description 2
- 244000024873 Mentha crispa Species 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 2
- 240000008790 Musa x paradisiaca Species 0.000 claims description 2
- 235000015266 Plantago major Nutrition 0.000 claims description 2
- 244000292697 Polygonum aviculare Species 0.000 claims description 2
- 235000006386 Polygonum aviculare Nutrition 0.000 claims description 2
- 235000010401 Prunus avium Nutrition 0.000 claims description 2
- 244000007021 Prunus avium Species 0.000 claims description 2
- 235000005805 Prunus cerasus Nutrition 0.000 claims description 2
- 244000207449 Prunus puddum Species 0.000 claims description 2
- 235000009226 Prunus puddum Nutrition 0.000 claims description 2
- 241000220317 Rosa Species 0.000 claims description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 2
- 240000002657 Thymus vulgaris Species 0.000 claims description 2
- 240000000377 Tussilago farfara Species 0.000 claims description 2
- 235000004869 Tussilago farfara Nutrition 0.000 claims description 2
- 235000009108 Urtica dioica Nutrition 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 235000020230 cinnamon extract Nutrition 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 239000001102 lavandula vera Substances 0.000 claims description 2
- 235000018219 lavender Nutrition 0.000 claims description 2
- 235000001510 limonene Nutrition 0.000 claims description 2
- 229940087305 limonene Drugs 0.000 claims description 2
- 239000001585 thymus vulgaris Substances 0.000 claims description 2
- 240000004160 Capsicum annuum Species 0.000 claims 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims 1
- 241001456088 Hesperocnide Species 0.000 claims 1
- 240000004760 Pimpinella anisum Species 0.000 claims 1
- 235000012550 Pimpinella anisum Nutrition 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 abstract description 3
- 229930005346 hydroxycinnamic acid Natural products 0.000 abstract description 3
- DEDGUGJNLNLJSR-UHFFFAOYSA-N hydroxycinnamic acid group Chemical class OC(C(=O)O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 abstract description 3
- 235000010359 hydroxycinnamic acids Nutrition 0.000 abstract description 3
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 150000002989 phenols Chemical class 0.000 abstract description 2
- 238000004113 cell culture Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000000779 smoke Substances 0.000 description 45
- 239000000835 fiber Substances 0.000 description 18
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 17
- 230000003505 mutagenic effect Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 238000010953 Ames test Methods 0.000 description 8
- 231100000039 Ames test Toxicity 0.000 description 8
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003344 environmental pollutant Substances 0.000 description 8
- 231100000243 mutagenic effect Toxicity 0.000 description 8
- 231100000719 pollutant Toxicity 0.000 description 8
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 231100000219 mutagenic Toxicity 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010028400 Mutagenic effect Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000001087 glyceryl triacetate Substances 0.000 description 6
- 235000013773 glyceryl triacetate Nutrition 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 229960002622 triacetin Drugs 0.000 description 6
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 5
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 5
- 244000223014 Syzygium aromaticum Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 5
- 229940117916 cinnamic aldehyde Drugs 0.000 description 5
- 229920005610 lignin Polymers 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- OVOUKWFJRHALDD-UHFFFAOYSA-N 2-[2-(2-acetyloxyethoxy)ethoxy]ethyl acetate Chemical compound CC(=O)OCCOCCOCCOC(C)=O OVOUKWFJRHALDD-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 231100000299 mutagenicity Toxicity 0.000 description 4
- 230000007886 mutagenicity Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 229920001131 Pulp (paper) Polymers 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- FXFYOPQLGGEACP-UHFFFAOYSA-N 6-methylcoumarin Chemical compound O1C(=O)C=CC2=CC(C)=CC=C21 FXFYOPQLGGEACP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920003043 Cellulose fiber Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 2
- 229920002079 Ellagic acid Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 235000006990 Pimenta dioica Nutrition 0.000 description 2
- 240000008474 Pimenta dioica Species 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- -1 Zimtaldehyd Chemical compound 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000002592 antimutagenic agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000004132 ellagic acid Nutrition 0.000 description 2
- 229960002852 ellagic acid Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 2
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 2
- 150000004005 nitrosamines Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HMKKIXGYKWDQSV-KAMYIIQDSA-N alpha-Amylcinnamaldehyde Chemical compound CCCCC\C(C=O)=C\C1=CC=CC=C1 HMKKIXGYKWDQSV-KAMYIIQDSA-N 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002557 mineral fiber Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000008030 superplasticizer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical class OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000005418 vegetable material Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
- A24B15/301—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by aromatic compounds
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
- A24D3/00—Tobacco smoke filters, e.g. filter-tips, filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces for cigars or cigarettes
- A24D3/06—Use of materials for tobacco smoke filters
- A24D3/14—Use of materials for tobacco smoke filters of organic materials as additive
Definitions
- the present invention relates to tobacco products or tobacco products Similar goods with known antioxidants acting natural products and / or nature-identical synthetic products provided and intended for smoking, and methods of making these products.
- the human organism is a natural basic burden exposed to toxic substances and is therefore with a variety of mutagenic and carcinogenic substances, some of them on your own metabolism be formed by himself.
- the body's defense system is particularly important, which are also influenced individually by the way of life can.
- the food intake in the body a number of chemical reactions, whereby mutagen and antimutagen acting substances are closely interrelated.
- tobacco products are both cigarettes, cigarillos and tobacco cartridges (so-called plug-in cigarettes) with or without a filter as well Fine cut and pipe tobacco made entirely or in part of tobacco and / or another smokable material, as well as tobacco products Similar tobacco products such as “Kretek” cigarettes with the addition of up to 50% by weight of smokable spices, or to understand pure, tobacco-free plant cigarettes.
- WPI KIKKOMAN CORP describes the use of a tobacco filter, on which ellagic acid is applied in an amount of 1 - 20mg. This is said to stimulate tobacco smoke reduced and mildness added to the tobacco smoke without the Change the taste and smell of the smoke.
- ellagic acid namely a strong blood coagulation activity and an antioxidant Effect; but it is very expensive, which is known to the expert is so that under no circumstances will he think of this in to use such a high concentration in smoking articles.
- WPI NAKAJIMA discloses that a cigarette has a substance add to remove the harmful substances from the smoke can.
- the substance mentioned there is a mixture of different Individual components, to which ascorbic acid and Vanillin belong without knowing more about these individual components Statements would have been made.
- the object of the present invention is therefore in Creation of another tobacco product containing additives which further reduces the potential risks of smoking be, as well as in the provision of a method for manufacturing such tobacco products.
- they are antioxidative acting natural products and / or nature-identical synthesis products the same in the tobacco product in combination of one or more antioxidant vitamins and one or more contain other natural products of plant origin, where their relative amounts based on the total weight in Dependency of the intended target component or components of a smokable tobacco product may vary.
- the natural substances can be found in the smoking tobacco including the common additives as well as in individual the main stream smoke accessible components of tobacco products such as filters, Wrapping papers, substrates, seam glue etc. in a known manner Be incorporated or upgraded in a way that is beneficial to both Manufacturer of the tobacco product as well as proportionately with it Suppliers can happen.
- the pure natural substances When the pure natural substances are added to tobacco, lies their preferred relative amount in the range of 0.1 per thousand to 25 wt .-%, with a content between 1 and 5 wt .-% particularly is preferred.
- the preferred amounts are 0.1 to 50 wt .-%, with amounts of 1 to 20 wt .-% particularly preferred are.
- the filter used can be a chamber filter, a Cellulose acetate filter or a cellulose tangled fiber filter or a multiple filter, preferably a double filter (each with or without filter ventilation), the double filter a higher strand-side draw resistance and a lower one mouth-side draw resistance and an overall filter efficiency of 80 - 99%. Filters from other sources can also be used known filter materials in combination with the antioxidative acting natural substances are used.
- the natural substances according to the invention are contained from the outset in non-tobacco-containing, predominantly plant-based, smokable materials that are added to the tobacco, or alternatively the smokable mixture consists exclusively of optionally different, coordinated, non-tobacco-containing, plant-based materials with or without plant-specific, natural substances according to the invention, then also apply the preferred amounts of 0.1 per mille to 25% by weight, based on the pure natural substances, as well as the particularly preferred amounts of use of 1.0 to 5% by weight, the intended use amount in all cases by adding the pure natural substances or the pure substances according to the invention can be added to the smokable mixture.
- the substances of the invention Production of a smokable mixture in a manner known per se be added to the leaf cut and / or the rib cut, optionally using known adhesives and binders.
- the substances can be used in film or Tape tobacco are incorporated, which is particularly the case with offers the use of solid, ground natural products.
- a new type of plant foil that does not contain tobacco be at least partially the natural substances according to the invention in the form of herbal ingredients from parts of the contains vegetable film material.
- smokable base material a mixture of lamina tobacco or a mixture of lamina tobacco and foil tobacco or a tobacco-free Mixture of plant material, which comes from coltsfoot, Peppermint, nettle, white plantain, spearmint, Lavender, thyme, sweet or sour cherry leaves, knotweed leaves, Derived from rose petals, allspice leaves or cinnamon bark.
- the smokable material is a Combination of tobacco blend and tobacco-free blend is.
- the substances according to the invention can be in liquid form the casing and / or flavorings are added, whereby can even replace them.
- the usual filter systems essentially consist of either a filter fiber tow made from cellulose acetate fibers or from each other matted cellulose fibers, which are a cellulose tangled fiber fleece surrender.
- the filter fiber tow is usually during the manufacture of the cigarette filter with one of the permissible Sprayed harder to cross-link the fibers and thus the filter to harden.
- These hardeners mostly consist of triacetin or Triethylene glycol diacetate (TEGDA) and can according to the invention for Part or all of the natural substances according to the invention in liquid form, if they dissolve in the hardener or even act as a hardener, such as eugenol.
- Natural substances like eugenol, or in common hardeners like TEGDA can in turn be other natural substances such as cinnamaldehyde, ethyl vanillin, but also ⁇ -tocopherol, tocopherol acetate, Tocopherol succinate, retinol and retinol palmitate be solved so that bi- or ternary or multiple Mixtures of solutions result, which advantageously both as hardeners for cellulose acetate fibers as well as casing materials for smokable mixtures can be used.
- Suspensions of solid natural substances can also be used in the hardener, but also scattering of ground natural substances in filter fiber tow from cellulose acetate fibers.
- Flavoring Eugenol The different solubilities and miscibilities of some Flavorings and vitamins preferred according to the invention in or with the usual hardener substances triacetin and TEGDA as well as the natural usable according to the invention even as a hardening substance Flavoring Eugenol are shown in Table 2. From the Data in Table 2 are in particular the excellent solubilizers Properties of the hardener according to the invention or hardener component of usable eugenols. The However, substance eugenol can also be in the form of a mixture with others in Tables 2 and 3 as hardeners or solvents listed substances are used, the concrete Mixtures and their respective proportions taking into account their properties and their market prices as well as depending of the component or components to be treated of the invention Product can be easily selected.
- Particularly preferred is a mixture of 80 parts triacetin, 15 parts eugenol and 5 parts of ⁇ -tocopherol acetate.
- the in this ratio mixed substances result in a clear solution from which after abandonment on cellulose acetate fibers preferred triacetin and Diffuse eugenol into the interior of the fibers, creating the ⁇ -tocopherol acetate enriched on the surface of the filter fibers , and therefore particularly easy from here as an emitter acting "filter" can be transferred into the main stream smoke can.
- the filter to be used in the process for producing a tobacco product does not consist of cellulose acetate fibers, it and / or the other components of the later product, such as the smokable tobacco-containing or tobacco-free vegetable material, the cigarette paper and the suture to be used, are mixed according to the invention with a solution of the inventive ones Flavorings and vitamins (or provitamins) are treated, whereby individual representatives of these groups of substances can in turn be used as solvents.
- the respective solubilities and miscibilities of the entire substances in or with some of the natural substances which can also be used as solvents according to the invention are shown in Table 3.
- the inventive Substances already on the part of the filter material manufacturer be worked into the fleece.
- the solid substances according to the invention can, for example, in granular shape with a grain diameter of about 0.8 mm on the part of the filter rod manufacturer introduced into the chambers of chamber filters liquid substances according to the invention, taken up, for example, from wood flour or lignin granules, lignin which is particularly suitable or has a lot of antioxidant activity containing wood particles in fiber-dust or granulate form also solitary as chamber embedding materials or as self-supporting, porous or smoke-permeable press hinge in the desired Filter format can be used. Furthermore, also that which comes into contact with the main stream smoke when smoking Inside of the filter wrapping paper with the inventive Natural substances can be coated.
- the cigarette paper can with the natural substances according to the invention in encapsulated or unencapsulated form in a manner known per se Be provided in this way, both single and two-layer Cigarette papers are suitable.
- the inner tobacco rod wrapper which also mesh-like or highly porous (10 - 20,000 CORESTA) can be provided with the substances according to the invention.
- This net-like inner tobacco rod wrapping can predominantly or for Entirely made of a suitable antioxidant containing lignin Wood pulp are made, at least partially the fiber content of otherwise customary cigarette papers made from suitable unbleached lignin wood pulp.
- the test principle essentially consists in the fact that histidine auxotrophic (his - ) indicator bacteria of the species Salmonella typhimurium mutate back into their prototrophic form (his + ) under the influence of mutagenic substances. Carrying out the Ames test, with or without “S 9 activation", allows a statement to be made as to whether a test substance is mutagenic in its original form or only after metabolism.
- the tobacco product proposed according to the invention points the traditional products have a greatly reduced risk potential on, because the natural substances used their antioxidations Properties on a variety of undesirable substances exercise and exert their effects at the place of metabolism.
- the Ames test was used to determine the mutagenic effect (loc. cit.) in the version "plate incorporation" as below described.
- test batches in petri dishes were evenly distributed on an agar which only allowed the growth of the his + back mutants.
- the petri dishes were subsequently incubated at 37 ° C in the dark for 48 hours. After the incubation period, the colonies formed from individual his + back-mutated bacteria were counted.
- the mutation frequency is the measure of the mutagenic activity.
- FIGS Some of the substances according to the invention with antimutagenic activity shown on smoke condensate.
- Scopoletin (7-hydroxy-6-methoxycoumarin) with a melting point of 205 ° C, without boiling point, is a natural plant ingredient in Virginia tobacco in a concentration of about Contain 300 ppm.
- scopoletin to detect the mainstream smoke, three versions of Trial cigarettes based on the same lot of cigarettes as prepared in Example 1.
- the concentration to scopoletin of tobacco by spraying on an ethanolic Solution of Scopoletin on the original cigarette tobacco Increased 330 ppm to 630 ppm and 5.330 ppm.
- the manufactured Cigarettes were smoked as described in Example 1, whereby the collected smoke condensate is dissolved in methanol has been.
- the filter sleeve design data corresponded to that of the example 1, the strand weight decreased to 930 ⁇ 20 mg, the amount of tobacco smoked was 785 mg.
- Cut tobacco with additions of cloves, cinnamon sticks and eugenol mixture Composition of the cut tobacco mixture Tobacco (% tr.) Cloves (% Tr.) Cinnamon sticks (% Tr.) added pure eugenol (% Tr.) 1 70 30th --- --- 2nd 70 --- 30th --- 3rd 70 15 15 --- 4th 94.9 --- --- 5.1 5 100 --- --- --- --- ---
- the experimental cigarettes were smoked under standard conditions (see example 1).
- the resulting smoke condensate solutions were examined with the Ames test according to Example 2, and in the embodiment "with S9 activation".
- the test results are shown graphically in FIG.
- the mutagenicity of the smoke condensate of mixture 1 was increased 55.5% of the effect of the comparison diminished, which corresponds to the explain the amount of eugenol contained in the cloves.
- the used Carnations had an eugenic content of 17.0%. In contrast this can be accompanied by the surprising reduction in mutagenicity of the smoke condensate of mixture 2 to 65.3% not alone with the amounts of cinnamaldehyde and eugenol contained.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Manufacture Of Tobacco Products (AREA)
- Cigarettes, Filters, And Manufacturing Of Filters (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft Tabakerzeugnisse oder Tabakerzeugnissen ähnliche Waren, die mit an sich bekannten antioxidativ wirkenden Naturstoffen und/oder naturidentischen Syntheseprodukten derselben versehen und zum Rauchen bestimmt sind, sowie Verfahren zur Herstellung dieser Erzeugnisse.The present invention relates to tobacco products or tobacco products Similar goods with known antioxidants acting natural products and / or nature-identical synthetic products provided and intended for smoking, and methods of making these products.
Der menschliche Organismus ist einer naturgegebenen Grundbelastung mit toxischen Substanzen ausgesetzt und wird daher mit einer Vielzahl von mutagenen und kanzerogenen Stoffen konfrontiert, die auf dein Wege des eigenen Stoffwechsels sogar zum Teil von ihm selbst gebildet werden.The human organism is a natural basic burden exposed to toxic substances and is therefore with a variety of mutagenic and carcinogenic substances, some of them on your own metabolism be formed by himself.
Der Mensch verfügt jedoch über verschiedene Abwehrmechanismen auf immunologischer, zellulärer und genetischer Ebene, um z.B. einer allergischen Reaktion, einer Zellschädigung oder einem Mutationsereignis im Bereich der Erbinformationen entgegenzuwirken. So existieren in den Zellen beispielsweise sogenannte "repair-Systeme", mit deren Hilfe Erbgutveränderungen erkannt und eliminiert werden können. However, humans have various defense mechanisms at the immunological, cellular and genetic level, e.g. an allergic reaction, cell damage or Counteract mutation event in the field of genetic information. For example, so-called "repair systems" exist in the cells, with the help of genetic changes recognized and can be eliminated.
Lange Zeit wurde davon ausgegangen, daß zwischen der Einwirkung etwaiger Risikofaktoren wie z.B. diversen Produkten unvollständiger Verbrennung, verschiedenen Strahlungen und/oder elektromagnetischen Feldern, einigen Pflanzen- und Holzschutzmitteln, bestimmten Mineralfasern (z.B. Asbest) und bestimmten Stoffwechselprodukten von Schimmelpilzen (z.B. Aflatoxin) auf den menschlichen Organismus und der Krebsentstehung ein direkter kausaler Zusammenhang besteht. Die Tatsache, daß die überwiegende Zahl der Menschen, die diesen Risikofaktoren ausgesetzt sind, nicht die zu erwartenden Symptome aufweist, hat jedoch zu einem Umdenken in der Risikobewertung geführt. So kann die Höhe des Krebsrisikos nicht mehr allein vom potentiellen Schadstoff bzw. Expositionsfaktor her definiert werden. Es muß vielmehr davon ausgegangen werden, daß sie das Ergebnis einer mulitifaktoriellen Wechselbeziehung zwischen einer Vielzahl einwirkender Substanzen/Mechanismen und belastetem Organismus ist. Ferner gilt als gesichert, daß mehrere Mutationsereignisse an bestimmten Stellen des Genoms erforderlich sind, damit aus einer normalen Körperzelle eine entartete Zelle mit unkontrolliertem Wachstum entstehen kann.For a long time it was assumed that between the action any risk factors such as various products incomplete Combustion, various radiations and / or electromagnetic Fields, some plant and wood preservatives, certain mineral fibers (e.g. asbestos) and certain metabolic products from mold (e.g. aflatoxin) to human Organism and the development of cancer a direct causal Connection exists. The fact that the vast number of people who are exposed to these risk factors has the expected symptoms, but has to rethink performed in the risk assessment. So the level of cancer risk no longer solely from the potential pollutant or exposure factor be defined here. Rather, it must be assumed be that they are the result of a multi-factorial Interrelationship between a multitude of acting substances / mechanisms and contaminated organism. Furthermore, is considered assured that multiple mutation events occur at specific locations of the genome are required to get out of a normal body cell a degenerate cell with uncontrolled growth arise can.
Besondere Bedeutung kommt dem körpereigenen Abwehrsystem zu, welches auch durch die Lebensweise individuell beeinflußt werden kann. So löst z.B. die Nahrungsaufnahme im Körper eine Reihe von chemischen Reaktionen aus, wobei sich mutagen und antimutagen wirkende Substanzen in enger Wechselbeziehung zueinander befinden.The body's defense system is particularly important, which are also influenced individually by the way of life can. For example, the food intake in the body a number of chemical reactions, whereby mutagen and antimutagen acting substances are closely interrelated.
Inzwischen wurden chemische Verbindungen identifiziert, die eine protektive Wirkung gegenüber mutagen wirkenden Stoffen aufweisen wie z.B. verschiedene Vitamine, Senföle und Beta-Carotin. Auch werden in Nahrungsmitteln enthaltene natürlich vorkommende pflanzliche Phenole wie z.B. Hydroxyzimtsäuren und deren Verbindungen aufgrund ihrer antioxidativen Eigenschaften als antimutagene und antikarzinogene Substanzen unterschiedlicher Intensität diskutiert (Karl Herrmann, "Hydroxyzimtsäure-Verbindungen als biologisch aktive Inhaltsstoffe von Lebensmitteln", Ernährungs-Umschau 38, Heft 4, S. 148-154 (1991)). Diese Erkenntnisse stützen sich u.a. auf epidemiologische Befunde, die ein umgekehrtes Verhältnis zwischen dem Konsum von Obst und Gemüse und verschiedenen Krebserkrankungen erkennen lassen.Chemical compounds have now been identified, one have a protective effect against mutagenic substances such as. various vitamins, mustard oils and beta-carotene. Also are naturally occurring in foods vegetable phenols such as Hydroxycinnamic acids and their compounds due to their antioxidant properties as antimutagenic and anticarcinogenic substances of different intensities discussed (Karl Herrmann, "Hydroxycinnamic acid compounds as biologically active ingredients in food ", nutritional survey 38, No. 4, pp. 148-154 (1991)). This knowledge support each other on epidemiological evidence that is an inverse Relationship between fruit and vegetable consumption different types of cancer.
Unter dem in dieser Beschreibung verwendeten Begriff "Tabakerzeugnisse" sind sowohl Cigaretten, Cigarillos und Tabakpatronen (sogenannte Steck-Cigaretten) mit oder ohne Filter als auch Feinschnitt und Pfeifentabak, die ganz oder anteilig aus Tabak und/oder einem anderen rauchbaren Material bestehen, sowie Tabakerzeugnissen ähnliche Rauchwaren wie beispielsweise "Kretek"-Cigaretten mit Zusatz von bis zu 50 Gew.% rauchbarer Gewürze, oder reine, tabakfreie Pflanzencigaretten zu verstehen.Under the term "tobacco products" used in this description are both cigarettes, cigarillos and tobacco cartridges (so-called plug-in cigarettes) with or without a filter as well Fine cut and pipe tobacco made entirely or in part of tobacco and / or another smokable material, as well as tobacco products Similar tobacco products such as "Kretek" cigarettes with the addition of up to 50% by weight of smokable spices, or to understand pure, tobacco-free plant cigarettes.
Es ist bekannt, daß auch die Konsumenten von rauchbaren Tabakerzeugnissen eine Vielzahl von organischen Verbindungen aufnehmen, von denen einige ein toxisches Potential für den menschlichen Organismus aufweisen, andere hingegen dieses reduzieren können. Bei der Diskussion über die gesundheitsgefährdenden Eigenschaften von Tabakerzeugnissen ist lange Zeit insbesondere die mutagene und krebsfördernde Wirkung einiger der durch Inhalation in den menschlichen Körper gelangenden Tabakinhaltsstoffe in den Vordergrund gestellt worden. Wie bereits ausgeführt, besteht zwischen der Einwirkung von Schadstoffen und der Krebsentstehung jedoch kein direkter kausaler Zusammenhang.It is known that consumers of smokable tobacco products absorb a variety of organic compounds some of which are toxic to humans Show organism, others reduce this can. When discussing the health hazardous Properties of tobacco products have long been special the mutagenic and cancer-promoting effects of some of them through inhalation tobacco ingredients entering the human body been put in the foreground. As already stated, exists between the effects of pollutants and the development of cancer however, no direct causal relationship.
Zahlreiche Versuchsreihen haben zu dem Ergebnis geführt, daß die in einem Tabakerzeugnis vorhandenen und entweder in der Gas- oder Partikelphase des Hauptstromrauches in den Organismus des Konsumenten gelangenden Stoffe bzw. Verbindungen nicht auf direktem Wege in der Lage sind, eine normale Zelle des menschlichen Organismus in eine entartete Zelle umzuformen.Numerous series of tests have led to the result that the existing in a tobacco product and either in the gas or Particulate phase of the mainstream smoke in the organism of the Consumers do not get substances or compounds directly Ways are able to a normal human cell To transform the organism into a degenerate cell.
Demgemäß ist festzustellen, daß die in Laborversuchen nachweisbare mutagene Wirkung von Inhaltsstoffen des Hauptstromrauches von Tabakerzeugnissen nicht unmittelbar mit einer kanzerogenen Wirkung gleichzusetzen ist, da die meisten in diesem Zusammenhang zu nennenden Substanzen und Stoffgruppen ihr gefährdendes Potential erst durch den zelleigenen Metabolismus dieser Verbindungen entfalten. Diese Erkenntnisse über die mutagene Wirkung wurden mit Hilfe des allgemein bekannten Ames-Test gewonnen (D.M. Maron and B.N. Ames, "Revised Methods for the Salmonella Mutagenicity Test", Handbook of Mutagenicity Test procedures, Elsevier Science Publishers BV, Her. B.J. Kilbey, M. Legator, W. Nichols und C. Ramel, 1984).Accordingly, it can be established that the detectable in laboratory tests mutagenic effects of mainstream smoke ingredients of tobacco products not directly related to a carcinogen Effect is equated as most in this context substances and groups of substances to be named Potential only through the cell's own metabolism of these compounds unfold. These findings about the mutagenic effect were obtained using the well-known Ames test (D.M. Maron and B.N. Ames, "Revised Methods for the Salmonella Mutagenicity Test ", Handbook of Mutagenicity Test procedures, Elsevier Science Publishers BV, Her.B.J. Kilbey, M. Legator, W. Nichols and C. Ramel, 1984).
Zur Reduzierung des Risikopotentials von rauchbaren Tabakerzeugnissen sind bisher verschiedene Wege beschritten worden.To reduce the risk potential of smokable tobacco products So far, different paths have been followed.
Zum einen wurden neue Filtersysteme geschaffen, durch die bestimmte Schadstoffgruppen daran gehindert werden, in den Hauptstromrauch und damit in den Respirationstrakt des Konsumenten zu gelangen. So wird beispielsweise in der DE-PS 35 32 618 eine Dotierung der Filter von Filtercigaretten mit beispielsweise L-Ascorbinsäure offenbart, wodurch die Absenkung von Aldehyden des Hauptstromrauches von Cigaretten erheblich begünstigt werden soll. Aus der WO 89/01301 ist es bekannt, Filter von Filtercigaretten mit Ethanol und andere Alkohole enthaltenden Mikro- und Makrokapseln zu präparieren, um das Lungengewebe vor bestimmten toxischen Bestandteilen des Cigarettenrauches wie insbesondere Nitrosaminen durch vorherige "Blockierung" der betroffenen bzw. zugänglichen Areale mit bestimmten im Hauptstromrauch freigesetzten Alkoholen zu schützen.On the one hand, new filter systems were created, through which certain Pollutant groups are prevented from entering the mainstream smoke and thus into the respiratory tract of the consumer reach. For example, in DE-PS 35 32 618 Doping the filter of filter cigarettes with, for example, L-ascorbic acid discloses, whereby the lowering of the aldehydes of the Main stream smoke from cigarettes are significantly favored should. From WO 89/01301 it is known to filter filter cigarettes with micro and alcohol containing ethanol and other alcohols Macrocapsules to prepare the lung tissue in front of certain toxic components of cigarette smoke such as in particular Nitrosamines by "blocking" the affected or accessible areas with certain released in the main stream smoke To protect alcohols.
Weiterhin wurde versucht, den Tabak von Filtercigaretten mit
bestimmten Stoffen zu imprägnieren, um bereits den Gehalt bestimmter
Schadstoffe im Hauptstromrauch zu reduzieren. So ist es
aus der OE-PS 340 297 und der OE-PS 240 298 bekannt, Tabak mit
Ascorbinsäure bzw. mit Salzen davon zu beauf schlagen, um den
Stickstoffdioxid-Gehalt des Cigarettenrauches zu reduzieren.
Ferner wurde gemäß EP-PS 0 116 085 ein Verfahren zur Imprägnierung
von Filtercigaretten mit Interferon oder biologisch
aktiven Fragmenten davon offenbart. Derartig behandelte Cigaretten
sollen die körpereigene Produktion von Interferon aktivieren
und somit das Immunsystem unterstützen.Furthermore, attempts were made to use the tobacco of filter cigarettes
impregnate certain substances in order to already determine the content of certain
Reduce pollutants in mainstream smoke. That's the way it is
known from OE-PS 340 297 and OE-
Auf diese Weise hergestellte Produkte tragen zwar dazu bei, potentielle
Risiken des Rauchens zu vermindern, sie beinhalten
aber auch systemimmanente Nachteile. Zum einen werden lediglich
bestimmte toxische Bestandteile überwiegend der Gasphase des
Cigarettenrauches im nichtverbrannten Abschnitt des Cigarettenstranges
(NO2) bzw. im Filter (Aldehyde) mittels Chemisorption
zurückgehalten, während der Gehalt des Hauptstromrauches an
anderen Schadstoffen jedoch nicht beeinflußt wird. Zum anderen
soll das Erzeugen einer "Schutzschicht" innerhalb des Organismus
gemäß WO 89/01301 wiederum nur gegenüber bestimmten Schadstoffen
wie beispielsweise den Nitrosaminen gelingen. Der Einsatz von
Interferon gemäß EP-PS 0 116 085 ist hingegen mit erheblichen
Kosten verbunden.Products manufactured in this way help to reduce the potential risks of smoking, but they also have inherent disadvantages in the system. On the one hand, only certain toxic components are predominantly retained in the gas phase of the cigarette smoke in the unburned section of the cigarette rod (NO 2 ) or in the filter (aldehydes) by means of chemisorption, while the content of the main stream smoke in other pollutants is not influenced. On the other hand, the creation of a "protective layer " within the organism according to WO 89/01301 should in turn only succeed against certain pollutants such as, for example, the nitrosamines. The use of interferon according to EP-
WPI KIKKOMAN CORP beschreibt die Verwendung eines Tabakfilters, auf den Ellagsäure aufgebracht ist, und zwar in einer Menge von 1 - 20mg. Dadurch soll die stimulierende Wirkung des Tabakrauchs gemindert und dem Tabakrauch Milde zugefügt werden, ohne den Geschmack und Geruch des Rauches zu verändern. Ellagsäure hat nämlich eine starke Blutkoagulationsaktivität und eine antioxidative Wirkung; sie ist aber sehr teuer, was dem Fachmann bekannt ist, so daß er in keinem Fall daran denken wird, diese in so hoher Konzentration bei Rauchartikeln einzusetzen.WPI KIKKOMAN CORP describes the use of a tobacco filter, on which ellagic acid is applied in an amount of 1 - 20mg. This is said to stimulate tobacco smoke reduced and mildness added to the tobacco smoke without the Change the taste and smell of the smoke. Has ellagic acid namely a strong blood coagulation activity and an antioxidant Effect; but it is very expensive, which is known to the expert is so that under no circumstances will he think of this in to use such a high concentration in smoking articles.
In WPI NAKAJIMA wird offenbart, einer Cigarette eine Substanz zuzusetzen, die schädliche Substanzen aus dem Rauch entfernen kann. Die dort erwähnte Substanz stellt eine Mischung aus verschiedenen Einzelbestandteilen dar, zu denen Ascorbinsäure und Vanillin gehören, ohne daß über diese Einzelbestandteile nähere Aussagen gemacht wären. WPI NAKAJIMA discloses that a cigarette has a substance add to remove the harmful substances from the smoke can. The substance mentioned there is a mixture of different Individual components, to which ascorbic acid and Vanillin belong without knowing more about these individual components Statements would have been made.
Die Aufgabe der vorliegenden Erfindung besteht daher in der Schaffung einer weiteren Rauchware, die Zusätze enthält, durch die die potentiellen Risiken des Rauchens weiter vermindert werden, sowie in der Bereitstellung eines Verfahrens zur Herstellung derartiger Rauchwaren.The object of the present invention is therefore in Creation of another tobacco product containing additives which further reduces the potential risks of smoking be, as well as in the provision of a method for manufacturing such tobacco products.
Zur Lösung dieser Aufgabe wird ein rauchbares Erzeugnis aus
Tabak und/oder einem anderen rauchbaren Material vorgeschlagen,
wobei der Tabak und/oder das rauchbare Material einen Zusatz von
antioxidativ wirkenden Naturstoffen und/oder naturidentischen
Syntheseprodukten derselben enthält, dadurch gekennzeichnet, daß
der Zusatz eine Kombination ist aus
Es wurde überraschenderweise gefunden, daß das erfindungsgemäße rauchbare Erzeugnis ein gegenüber herkömmlichen Produkten deutlich vermindertes Risikopotential aufweist. It has surprisingly been found that the inventive smokable product clearly compared to conventional products has reduced risk potential.
Die jeweiligen Molekulargewichte sowie Schmelz- und Siedepunkte der erfindungsgemäßen Naturstoffe der Gruppen (a) und (b) sind in Tabelle 1 aufgeführt.The respective molecular weights as well as melting and boiling points of the natural substances according to the invention of groups (a) and (b) listed in Table 1.
Nach einer bevorzugten Ausführungsform sind die antioxidativ wirkenden Naturstoffe und/oder naturidentischen Syntheseprodukte derselben in dem Tabakerzeugnis in Kombination eines oder mehrerer antioxidativ wirkender Vitamine und eines oder mehrerer weiterer Naturstoffe pflanzlichen Ursprungs enthalten, wobei deren relative, auf das Gesamtgewicht bezogene Einsatzmengen in Abhängigkeit des oder der vorgesehenen Zielkomponenten eines rauchbaren Tabakerzeugnisses variieren können. Grundsätzlich können die Naturstoffe sowohl in den Rauchtabak inklusive der gängigen Zuschlagsstoffe als auch in einzelne dem Hauptstromrauch zugängliche Komponenten der Tabakerzeugnisse wie Filter, Hüllpapiere, Trägerstoffe, Nahtleim etc. in an sich bekannter Weise eingearbeitet bzw. aviviert werden, was sowohl beim Hersteller des Tabakerzeugnisses als auch anteilig bei dessen Zulieferer geschehen kann.In a preferred embodiment, they are antioxidative acting natural products and / or nature-identical synthesis products the same in the tobacco product in combination of one or more antioxidant vitamins and one or more contain other natural products of plant origin, where their relative amounts based on the total weight in Dependency of the intended target component or components of a smokable tobacco product may vary. Basically The natural substances can be found in the smoking tobacco including the common additives as well as in individual the main stream smoke accessible components of tobacco products such as filters, Wrapping papers, substrates, seam glue etc. in a known manner Be incorporated or upgraded in a way that is beneficial to both Manufacturer of the tobacco product as well as proportionately with it Suppliers can happen.
Wenn die reinen Naturstoffe dem Tabak zugesetzt werden, liegt ihre bevorzugte relative Einsatzmenge im Bereich von 0,1 Promille bis 25 Gew.-%, wobei ein Gehalt zwischen 1 und 5 Gew.-% besonders bevorzugt ist. Werden die reinen Naturstoffe in den Filter oder in das Cigarettenpapier bzw. in den Leim der Cigarettennaht eingearbeitet, betragen die bevorzugten Mengen 0,1 bis 50 Gew.-%, wobei Mengen von 1 bis 20 Gew.-% besonders bevorzugt sind. Der verwendete Filter kann ein Kammerfilter, ein Celluloseacetatfilter oder ein Cellulose-Wirrfaservlies-Filter oder ein Mehrfachfilter, vorzugsweise ein Doppelfilter (jeweils mit oder ohne Filterventilierung) sein, wobei der Doppelfilter einen höheren strangseitigen Zugwiderstand und einen niedrigeren mundseitigen Zugwiderstand sowie einen Gesamtfilter-Wirkungsgrad von 80 - 99% aufweist. Ebenso können auch Filter aus anderen an sich bekannten Filtermaterialien in Kombination mit den antioxidativ wirkenden Naturstoffen eingesetzt werden.When the pure natural substances are added to tobacco, lies their preferred relative amount in the range of 0.1 per thousand to 25 wt .-%, with a content between 1 and 5 wt .-% particularly is preferred. Are the pure natural substances in the Filter or in the cigarette paper or in the glue of the cigarette seam incorporated, the preferred amounts are 0.1 to 50 wt .-%, with amounts of 1 to 20 wt .-% particularly preferred are. The filter used can be a chamber filter, a Cellulose acetate filter or a cellulose tangled fiber filter or a multiple filter, preferably a double filter (each with or without filter ventilation), the double filter a higher strand-side draw resistance and a lower one mouth-side draw resistance and an overall filter efficiency of 80 - 99%. Filters from other sources can also be used known filter materials in combination with the antioxidative acting natural substances are used.
Sind die erfindungsgemäßen Naturstoffe von vornherein in nichttabakhaltigen,
überwiegend pflanzlichen rauchbaren Materialien
enthalten, die dem Tabak zugesetzt werden, oder besteht alternativ
die rauchbare Mischung ausschließlich aus gegebenenfalls
verschiedenen, aufeinander abgestimmten, nichttabakhaltigen,
pflanzlichen Materialien mit oder ohne pflanzeneigenen, erfindungsgemäßen
Naturstoffen, so gelten ebenfalls die bevorzugten,
auf die reinen Naturstoffe zu beziehenden Einsatzmengen von 0,1
Promille bis 25 Gew.-%, ebenso die besonders bevorzugten Einsatzmengen
von 1,0 bis 5 Gew.-%, wobei in allen Fällen die vorgesehene
Einsatzmenge durch Zugabe der reinen Naturstoffe bzw.
der reinen erfindungsgemäßen Substanzen zur rauchbaren Mischung
ergänzt werden kann.
Beispielsweise können die erfindungsgemäßen Substanzen beim Fertigen einer rauchbaren Mischung auf an sich bekannte Weise dem Blattschnitt und/oder dem Rippenschnitt zugesetzt werden, gegebenenfalls unter Einsatz bekannter Haft- und Bindemittel. Alternativ können die Substanzen auf bekannte Weise in Folien- oder Bandtabak eingearbeitet werden, was sich insbesondere bei der Verwendung fester, gemahlener Naturstoffe anbietet. Hierbei kann auch eine neuartige, nichttabakhaltige Pflanzenfolie eingesetzt werden, die zumindest anteilig die erfindungsgemäßen Naturstoffe in Form pflanzeneigener Inhaltsstoffe von Teilen des pflanzlichen Folienmaterials enthält. Vorzugsweise ist das rauchbare Basis-Material eine Mischung aus Lamina-Tabaken oder eine Mischung aus Lamina-Tabak und Folientabak oder eine tabakfreie Mischung aus Pflanzenmaterial, welches sich von Huflattich, Pfefferminze, Brennessel, Breitwegerich, Krauseminze, Lavendel, Thymian, Süß- oder Sauerkirschblättern, Knöterichblättern, Rosenblättern, Pimentblättern oder Zimtrinde ableitet. Alternativ ist es bevorzugt, daß das rauchbare Material eine Kombination aus Tabakmischung und tabakfreier Mischung ist.For example, the substances of the invention Production of a smokable mixture in a manner known per se be added to the leaf cut and / or the rib cut, optionally using known adhesives and binders. Alternatively, the substances can be used in film or Tape tobacco are incorporated, which is particularly the case with offers the use of solid, ground natural products. Here can also use a new type of plant foil that does not contain tobacco be at least partially the natural substances according to the invention in the form of herbal ingredients from parts of the contains vegetable film material. Preferably that is smokable base material a mixture of lamina tobacco or a mixture of lamina tobacco and foil tobacco or a tobacco-free Mixture of plant material, which comes from coltsfoot, Peppermint, nettle, white plantain, spearmint, Lavender, thyme, sweet or sour cherry leaves, knotweed leaves, Derived from rose petals, allspice leaves or cinnamon bark. Alternatively, it is preferred that the smokable material is a Combination of tobacco blend and tobacco-free blend is.
Ferner können die erfindungsgemäßen Substanzen in flüssiger Form den Casing- und/oder Flavorstoffen zugesetzt werden, wobei sie diese sogar ersetzen können.Furthermore, the substances according to the invention can be in liquid form the casing and / or flavorings are added, whereby can even replace them.
Die üblichen Filtersysteme bestehen im wesentlichen entweder aus einem Filterfaser-Tow aus Celluloseacetatfasern oder aus miteinander verfilzten Cellulosefasern, die ein Cellulose-Wirrfaservlies ergeben. Das Filterfasertow wird normalerweise während der Fertigung des Cigarettenfilters mit einem der zulässigen Härter besprüht, um die Fasern zu vernetzen und damit den Filter zu härten. Diese Härter bestehen zumeist aus Triacetin oder Triethylenglykoldiacetat (TEGDA) und können erfindungsgemäß zum Teil oder vollständig durch die erfindungsgemäßen Naturstoffe in flüssiger Form ersetzt werden, sofern sie sich im Härter lösen oder aber selbst als Härter wirken wie beispielsweise Eugenol. In selber erfindungsgemäß als Härter einsetzbaren flüssigen Naturstoffen wie Eugenol, oder in üblichen Härtern wie TEGDA oder Triacetin können erfindungsgemäß wiederum andere Naturstoffe wie Zimtaldehyd, Ethylvanillin, aber auch α-Tocopherol, Tocopherolacetat, Tocopherolsuccinat, Retinol und Retinolpalmitat gelöst werden, so daß sich bi- oder ternäre oder multiple Lösungsgemische ergeben, die vorteilhafterweise sowohl als Härter für Celluloseacetatfasern als auch als Casingstoffe für rauchbare Mischungen eingesetzt werden können.The usual filter systems essentially consist of either a filter fiber tow made from cellulose acetate fibers or from each other matted cellulose fibers, which are a cellulose tangled fiber fleece surrender. The filter fiber tow is usually during the manufacture of the cigarette filter with one of the permissible Sprayed harder to cross-link the fibers and thus the filter to harden. These hardeners mostly consist of triacetin or Triethylene glycol diacetate (TEGDA) and can according to the invention for Part or all of the natural substances according to the invention in liquid form, if they dissolve in the hardener or even act as a hardener, such as eugenol. In liquid usable according to the invention as a hardener Natural substances like eugenol, or in common hardeners like TEGDA According to the invention, or triacetin can in turn be other natural substances such as cinnamaldehyde, ethyl vanillin, but also α-tocopherol, tocopherol acetate, Tocopherol succinate, retinol and retinol palmitate be solved so that bi- or ternary or multiple Mixtures of solutions result, which advantageously both as hardeners for cellulose acetate fibers as well as casing materials for smokable mixtures can be used.
Ferner sind Suspensionen fester Naturstoffe im Härter einsetzbar, aber auch Einstreuungen gemahlener Naturstoffe in Filterfaser-Tow aus Celluloseacetatfasern.Suspensions of solid natural substances can also be used in the hardener, but also scattering of ground natural substances in filter fiber tow from cellulose acetate fibers.
Die unterschiedlichen Löslichkeiten und Mischbarkeiten einiger erfindungsgemäß bevorzugter Aromastoffe und Vitamine in bzw. mit den üblichen Härtersubstanzen Triacetin und TEGDA sowie dem erfindungsgemäß selbst als Härtersubstanz verwendbaren natürlichen Aromastoff Eugenol sind in Tabelle 2 dargestellt. Aus den Daten der Tabelle 2 sind insbesondere die ausgezeichneten lösungsvermittelnden Eigenschaften des erfindungsgemäß als Härter bzw. Härterkomponente einsetzbaren Eugenols zu ersehen. Die Substanz Eugenol kann jedoch auch in Form einer Mischung mit anderen in den Tabellen 2 und 3 als Härter bzw. Lösungsmittel aufgeführten Stoffen Verwendung finden, wobei die konkreten Mischungen und ihre jeweiligen Anteile unter Berücksichtigung ihrer Eigenschaften und ihrer Marktpreise sowie in Abhängigkeit des bzw. der zu behandelnden Komponenten des erfindungsgemäßen Erzeugnisses leicht ausgewählt werden können. Besonders bevorzugt ist eine Mischung aus 80 Teilen Triacetin, 15 Teilen Eugenol und 5 Teilen α-Tocopherolacetat. Die in diesem Verhältnis gemischten Substanzen ergeben eine klare Lösung, aus welcher nach Aufgabe auf Celluloseacetatfasern bevorzugt Triacetin und Eugenol in das Innere der Fasern diffundieren, wodurch das α-Tocopherolacetat auf der Oberfläche der Filterfasern angereichert wird, und somit besonders leicht vom hier als Emittor wirkenden "Filter" in den Hauptstromrauch transferiert werden kann.The different solubilities and miscibilities of some Flavorings and vitamins preferred according to the invention in or with the usual hardener substances triacetin and TEGDA as well as the natural usable according to the invention even as a hardening substance Flavoring Eugenol are shown in Table 2. From the Data in Table 2 are in particular the excellent solubilizers Properties of the hardener according to the invention or hardener component of usable eugenols. The However, substance eugenol can also be in the form of a mixture with others in Tables 2 and 3 as hardeners or solvents listed substances are used, the concrete Mixtures and their respective proportions taking into account their properties and their market prices as well as depending of the component or components to be treated of the invention Product can be easily selected. Particularly preferred is a mixture of 80 parts triacetin, 15 parts eugenol and 5 parts of α-tocopherol acetate. The in this ratio mixed substances result in a clear solution from which after abandonment on cellulose acetate fibers preferred triacetin and Diffuse eugenol into the interior of the fibers, creating the α-tocopherol acetate enriched on the surface of the filter fibers , and therefore particularly easy from here as an emitter acting "filter" can be transferred into the main stream smoke can.
Wenn der im Verfahren zur Herstellung eines Tabakerzeugnisses zu
verwendende Filter nicht aus Celluloseacetatfasern besteht, wird
er und/oder die anderen Komponenten des späteren Erzeugnisses
wie das rauchbare tabakhaltige oder tabakfreie pflanzliche Material,
das Cigarettenpapier und der zu verwendende Nahtleim erfindungsgemäß
mit einer Lösung aus den erfindungsgemäßen Aromastoffen
und Vitaminen (bzw. Provitaminen) behandelt, wobei als
Lösungsmittel wiederum einzelne Vertreter dieser Stoffgruppen
verwendbar sind. Die jeweiligen Löslichkeiten und Mischbarkeiten
der gesamten Stoffe in bzw. mit einigen der erfindungsgemäß auch
als Lösungsmittel einsetzbaren Naturstoffe sind in Tabelle 3
dargestellt.
Bei Verwendung des Cellulose-Wirrfaservlieses können die erfindungsgemäßen Substanzen bereits seitens des Filtermaterialherstellers in das Vlies eingearbeitet werden. Hierbei können letztlich die üblicherweise gebleichten Cellulosefasern von beispielsweise einjährigen Pflanzen des bekannten Wirrfaservlieses anteilig oder überwiegend, vorzugsweise bis zu 85 % durch geeignete, ausreichend antioxidativ wirkendes Lignin enthaltende ungebleichte Holzschliff-"Fasern" ausgetauscht werden. Zudem können die erfindungsgemäßen festen Substanzen beispielsweise in gekörnter Form mit einem Korndurchmesser von etwa 0,8 mm seitens des Filterstabherstellers in die Kammern von Kammerfiltern eingebracht werden, ebenso erfindungsgemäße flüssige Substanzen, aufgenommen von beispielsweise Holzmehl- oder Ligningranulat, wobei besonders geeignete bzw. viel antioxidativ wirkendes Lignin enthaltende Holzteilchen in Faser-Staub- oder Granulatform dabei auch solitär als Kammereinlagerungsmaterialien oder als selbsttragende, poröse bzw. rauchdurchlässige Preßhinge im gewünschten Filterformat eingesetzt werden können. Ferner kann auch die beim Abrauchen mit dem Hauptstromrauch in Kontakt tretende Innenseite des Filterumhüllungspapiers mit den erfindungsgemäßen Naturstoffen beschichtet sein.When using the cellulose random fiber fleece, the inventive Substances already on the part of the filter material manufacturer be worked into the fleece. Here you can ultimately the usually bleached cellulose fibers from for example annual plants of the well-known tangled fiber fleece proportionately or predominantly, preferably up to 85% suitable lignin containing sufficient antioxidant activity unbleached wood pulp "fibers" are exchanged. In addition the solid substances according to the invention can, for example, in granular shape with a grain diameter of about 0.8 mm on the part of the filter rod manufacturer introduced into the chambers of chamber filters liquid substances according to the invention, taken up, for example, from wood flour or lignin granules, lignin which is particularly suitable or has a lot of antioxidant activity containing wood particles in fiber-dust or granulate form also solitary as chamber embedding materials or as self-supporting, porous or smoke-permeable press hinge in the desired Filter format can be used. Furthermore, also that which comes into contact with the main stream smoke when smoking Inside of the filter wrapping paper with the inventive Natural substances can be coated.
Das Cigarettenpapier kann mit den erfindungsgemäßen Naturstoffen in verkapselter oder unverkapselter Form in an sich bekannter Weise versehen werden, wobei hierfür sowohl ein- als auch zweilagige Cigarettenpapiere geeignet sind. Im letzteren Fall wird vorzugsweise die innen liegende Tabakstrangumhüllung, welche auch netzartig oder hochporös (10 - 20.000 CORESTA) ausgebildet sein kann, mit den erfindungsgemäßen Substanzen versehen. Diese netzartige innere Tabakstrangumhüllung kann überwiegend oder zur Gänze auch aus geeignetem, antioxidativ wirkenden Lignin enthaltendem Holzschliff gefertigt werden, ebenso zumindest anteilig der Fasergehalt ansonsten üblicher Cigarettenpapiere aus geeignetem ungebleichten ligninhaltigem Holzschliff bestehen. The cigarette paper can with the natural substances according to the invention in encapsulated or unencapsulated form in a manner known per se Be provided in this way, both single and two-layer Cigarette papers are suitable. In the latter case preferably the inner tobacco rod wrapper, which also mesh-like or highly porous (10 - 20,000 CORESTA) can be provided with the substances according to the invention. This net-like inner tobacco rod wrapping can predominantly or for Entirely made of a suitable antioxidant containing lignin Wood pulp are made, at least partially the fiber content of otherwise customary cigarette papers made from suitable unbleached lignin wood pulp.
Schließlich kann auch der im Bereich der Cigarettennaht zur Verklebung der Tabakstrangumhüllung eingesetzte Leim die erfindungsgemäßen Naturstoffe in flüssiger oder feingemahlener Form beinhalten. Hierbei hat sich gezeigt, daß die technischen Eigenschaften derart behandelter Leime sogar verbessert werden können.Finally, in the area of the cigarette seam Gluing the tobacco rod wrapping used glue the invention Natural substances in liquid or finely ground form include. It has been shown that the technical properties glues treated in this way can even be improved.
Nach dem Grundgedanken der Erfindung wird beim Konsumieren bzw. Abrauchen des erfindungsgemäßen Tabakerzeugnisses dessen Hauptstromrauch mit den an sich bekannten antioxidativ wirkenden Naturstoffen angereichert, wodurch bewirkt wird, daß die durch den Hauptstromrauch freigesetzten antimutagenen Substanzen näherungsweise zeitgleich mit den potentiellen Schadstoffen des Hauptstromrauches dem Organismus am Ort der Verstoffwechselung zur Verfügung stehen und somit spontan eine mögliche mutagene Wirkung der unerwünschten kritischen Substanzen weitgehend kompensiert wird. Dies bedeutet, daß bei einer vergleichsweise geringen Menge an antimutagen wirkenden Substanzen die gleiche Wirkung erzeugt wird, als wenn nachträglich eine entsprechend größere Menge dieser Substanzen dem Organismus zur Verfügung gestellt würde.According to the basic idea of the invention, when consuming or Smoking the tobacco product according to the main stream smoke with the known antioxidant Enriched with natural substances, which causes the through the main current smoke released antimutagenic substances approximately at the same time as the potential pollutants of the Mainstream smoke to the organism at the place of metabolism are available and thus spontaneously a possible mutagenic Effect of the undesirable critical substances largely compensated becomes. This means that at a comparative small amount of antimutagenic substances the same Effect is created as if afterwards a corresponding larger quantities of these substances are available to the organism would be asked.
Eine wesentliche Voraussetzung für den praxisbezogenen Einsatz der erfindungsgemäß verwendeten Naturstoffe ist deren ausreichender Übergang in den Hauptstromrauch. Experimentelle Befunde haben ergeben, daß diese Voraussetzung von den eingesetzten Naturstoffen erfüllt wird (vgl. Beispiel 4). Zudem hat sich gezeigt, daß der Übergang in den Hauptstromrauch von in Pflanzenteilen inkorporierten erfindungsgemäßen Naturstoffen - beispielsweise das Pimentblatt-eigene Eugenol - noch erheblich begünstigt werden kann durch die Behandlung der entsprechenden Pflanzenteile nach einem der bekannten Bläh- oder Expansionsverfahren, vorzugsweise nach dem sogenannten INCOM - Verfahren der Anmelderin gemäß den Patentschriften DE-PS 29 03 300, DE-PS 31 19 330 und DE-PS 34 14 625. Hierbei werden relevante Inhaltsstoffe der Pflanzenteile "aufgeschlossen", d.h. sie können besonders leicht von auch nur geringen Mengen an Hauptstromrauch transferiert werden.An essential prerequisite for practical use the natural substances used according to the invention are more adequate Transition to mainstream smoke. Experimental findings have shown that this requirement of the used Natural products are fulfilled (see Example 4). In addition, has shown that the transition to mainstream smoke from in plant parts incorporated natural substances according to the invention - for example the allspice leaf's own eugenol - still considerable can be favored by treating the appropriate Plant parts according to one of the known expansion or expansion processes, preferably according to the so - called INCOM method of Applicant according to the patents DE-PS 29 03 300, DE-PS 31 19 330 and DE-PS 34 14 625. Here are relevant ingredients of the plant parts "open minded", i.e. they can be easily removed from even just small amounts of mainstream smoke are transferred.
Überraschenderweise hat sich gezeigt, daß das mutagene Potential der erfindungsgemäß angereicherten Tabakerzeugnisse in signifikanter Weise reduziert werden konnte. Zum Nachweis dieser antimutagenen Wirkung wurde als aussagekräftiger Schnelltest der Ames-Test durchgeführt (a.a.O.).Surprisingly, it has been shown that the mutagenic potential of the tobacco products enriched according to the invention in significant Way could be reduced. To detect this antimutagenic Effect was as a meaningful quick test of the Ames test carried out (op. Cit.).
Das Testprinzip besteht im wesentlichen darin, daß Histidinauxotrophe (his-) Indikatorbakterien der Art Salmonella typhimurium unter dem Einfluß mutagen wirkender Stoffe in ihre prototrophe Form (his+) rückmutieren. Die Durchführung des Ames-Tests, ohne bzw. mit "S 9-Aktivierung", erlaubt eine Aussage darüber, ob eine Testsubstanz in ihrer Ausgangsform oder erst nach Verstoffwechselung mutagen ist.The test principle essentially consists in the fact that histidine auxotrophic (his - ) indicator bacteria of the species Salmonella typhimurium mutate back into their prototrophic form (his + ) under the influence of mutagenic substances. Carrying out the Ames test, with or without "S 9 activation", allows a statement to be made as to whether a test substance is mutagenic in its original form or only after metabolism.
Mit diesem Testsystem wurde nachgewiesen, daß die in Lösungsmittel aufgefangene Partikelphase von Tabakrauch nur in verstoffwechseltem Zustand mutagen wirkt (vgl. Shigeaki Sato et al., "Mutagenicity of smoke condensates from cigarettes, cigars and pipe tobacco", Cancer Lett. 3, S. 1-8, 1977).This test system was used to demonstrate that the solvent trapped particle phase of tobacco smoke only in metabolized The condition is mutagenic (cf. Shigeaki Sato et al., "Mutagenicity of smoke condensates from cigarettes, cigars and pipe tobacco ", Cancer Lett. 3, pp. 1-8, 1977).
Es gilt als gesichert, daß die meisten Substanzen mit antimutagener Wirksamkeit im Ames-Test im menschlichen Organismus eine protektive Wirkung ausüben bzw. zur Stärkung des körpereigenen Abwehrsystems beitragen können (vgl. z.B. B.N. Ames, "Dietary Carcinogens and Anticarcinogens", SCIENCE, Bd. 221, S. 1256 - 1264, 1983). Die im menschlichen Organismus mögliche Bildung von toxischen Stoffwechselprodukten aus Rauchinhaltsstoffen und die gezielte Verminderung der daraus resultierenden mutagenen Wirkung durch Zusatz von Antimutagenen kann im Ames-Test simuliert werden.It is considered certain that most substances with antimutagenic Effectiveness in the Ames test in the human organism exert a protective effect or to strengthen the body's own Defense system (cf. e.g. B.N. Ames, "Dietary Carcinogens and Anticarcinogens ", SCIENCE, Vol. 221, p. 1256 - 1264, 1983). The possible formation of in the human organism toxic metabolites from smoke ingredients and the targeted reduction of the resulting mutagenic effect by adding antimutagens can be simulated in the Ames test become.
Das erfindungsgemäß vorgeschlagene Tabakerzeugnis weist gegenüber den herkömmlichen Produkten ein stark vermindertes Risikopotential auf, da die verwendeten Naturstoffe ihre antioxidatiyen Eigenschaften auf eine Vielzahl unerwünschter Substanzen ausüben und ihre Wirkungen am Ort der Verstoffwechselung entfalten.The tobacco product proposed according to the invention points the traditional products have a greatly reduced risk potential on, because the natural substances used their antioxidations Properties on a variety of undesirable substances exercise and exert their effects at the place of metabolism.
Die Erfindung wird anhand der nachfolgenden Beispiele und der Figuren 1 bis 7 näher erläutert.The invention is illustrated by the following examples and Figures 1 to 7 explained in more detail.
Zur Vorbereitung des Ames-Tests wurden 20 unten näher spezifizierte
Cigaretten unter den üblichen Normbedingungen (ISO 4387,
Zugvolumen 35 ml, Zugzeit 2 Sekunden und Zugpause 58 Sekunden)
maschinell abgeraucht. Die sogenannte Partikelphase des Hauptstromrauches
(Rauchkondensat) wurde auf einem Cambridge-Glasfaserfilter
niedergeschlagen, mit 20 ml Dimethylsulfoxid abgelöst
und bis zum Gebrauch bei -20°C gelagert. Die nicht ventilierten
Filtercigaretten (Format 100 x 7,9 mm, Strang 75 mm lang, Filter
25 mm lang) besaßen ein Stranggewicht von 945 ± 10 mg (Virginia-Mischung),
die abgerauchte Tabakmenge lag bei 800 mg. Das 48 mg
schwere Cigarettenpapier besaß eine Porosität von 24 Coresta,
das Filtergewicht lag bei gerundet 180 mg, das Filtermaterial
bestand aus handelsüblichen Celluloseacetatfasern (3,0 Y / 35000),
der Härter war Triacetin (ca. 7 %).To prepare for the Ames test, 20 were specified below
Cigarettes under the usual standard conditions (ISO 4387,
Train volume 35 ml,
Zur Bestimmung der mutagenen Wirkung wurde der Ames-Test (a.a.O.) in der Version "plate incorporation" wie nachfolgend beschrieben durchgeführt.The Ames test was used to determine the mutagenic effect (loc. cit.) in the version "plate incorporation" as below described.
Zu jeweils 2 ml eines bei 43 °C temperierten Weichagars wurden 0,1 ml Übernachtkultur von Salmonella typhimurium, Stamm TA 98, 0,05 ml abgestuft verdünnte Rauchkondensat-Lösung gemäß Beispiel 1 und 0,5 ml S 9-Mix (Aktivierungssystem), bestehend aus 50 µl durch Zentrifugieren von Leberhomogenat Aroclor-vorbehandelter Ratten bei 9.000 g erhaltenen Überstand; 0,76 mg Glucose-6-Phosphat; 1,57 mg NADP; 0,81 mg MgCl2 · 6 H2O; 1,23 mg KCl in Phosphatpuffer pH 7,4, pipettiert. Nach kurzem Durchmischen wurden die Testansätze in Petrischalen gleichmäßig auf einen Agar verteilt, der nur das Wachstum der his+-Rückmutanten zuläßt. Die Petrischalen wurden nachfolgend 48 Stunden lang bei 37 °C im Dunkeln inkubiert. Nach Ablauf der Inkubationszeit wurden die aus einzelnen his+-rückmutierten Bakterien entstandenen Kolonien ausgezählt. Die Mutationshäufigkeit ist das Maß für die mutagene Aktivität.0.1 ml overnight culture of Salmonella typhimurium , strain TA 98, 0.05 ml graduatedly diluted smoke condensate solution according to Example 1 and 0.5 ml S 9 mix (activation system) were added to 2 ml each of soft agar tempered at 43 ° C. consisting of 50 µl by centrifuging liver homogenate Aroclor-pretreated rats with 9,000 g of supernatant obtained; 0.76 mg glucose-6-phosphate; 1.57 mg NADP; 0.81 mg MgCl 2 .6 H 2 O; Pipette 1.23 mg KCl in pH 7.4 phosphate buffer. After a short mixing, the test batches in petri dishes were evenly distributed on an agar which only allowed the growth of the his + back mutants. The petri dishes were subsequently incubated at 37 ° C in the dark for 48 hours. After the incubation period, the colonies formed from individual his + back-mutated bacteria were counted. The mutation frequency is the measure of the mutagenic activity.
Aus den in der nachfolgenden Tabelle 4 dargestellten Ergebnissen
ist ersichtlich, daß die im Rauchkondensat enthaltenen Stoffe
ihre mutagene Wirkung erst nach ihrer Verstoffwechselung entfalten.
(Mittelwerte aus Dreifachbestimmungen)
(Mean values from triplicate determinations)
Die Bewertung von erfindungsgemäßen Substanzen hinsichtlich ihrer antimutagenen Wirkungen erfolgte mit dem in Beispiel 2 beschriebenen Teatsystem, indem den Testansätzen mit den verschiedenen Kondensatmengen nun zusätzlich abgestufte Dosierungen der betreffenden Substanzen zugesetzt wurden. Dabei wurde sichergestellt, daß in einem für die Bakterien nicht toxischen Konzentrationsbereich gearbeitet wurde.The evaluation of substances according to the invention with regard to Their antimutagenic effects were the same as in Example 2 described Teatsystem by the test approaches with the different Condensate quantities now additionally graduated doses of the substances in question were added. It was ensured that in a nontoxic to the bacteria Concentration range was worked.
In den Figuren 1 bis 6 sind beispielhaft die Ergebnisse von einigen der erfindungsgemäßen Substanzen mit antimutagener Wirkung auf Rauchkondensat dargestellt.The results of FIGS some of the substances according to the invention with antimutagenic activity shown on smoke condensate.
Die Ergebnisse zeigen, daß die durch die im Rauchkondensat enthaltenen Schadstoffe verursachte Mutationshäufigkeit und damit das Gefährdungspotential durch die zugesetzten Naturstoffe entscheidend vermindert werden konnten.The results show that those contained in the smoke condensate Pollutants caused frequency of mutations and thus the risk potential from the added natural substances is decisive could be reduced.
Die zuzusetzenden Naturstoffe unterscheiden sich erheblich bezüglich ihrer Schmelz- und Siedepunkte (vgl. Tabelle 1). Um nachzuweisen, daß auch dem Tabak zugesetzte Substanzen in den Tabakrauch übergehen, die nicht destillierbar sind, wurde folgender Versuch durchgeführt:The natural substances to be added differ considerably in terms of their melting and boiling points (see Table 1). In order to prove that substances added to tobacco can also be found in the Pass tobacco smoke that cannot be distilled became the following Test carried out:
Scopoletin (7-Hydroxy-6-methoxycumarin) mit einem Schmelzpunkt von 205 °C, ohne Siedepunkt, ist als natürlicher Pflanzeninhaltsstoff in Virginiatabaken in einer Konzentration von etwa 300 ppm enthalten. Um den Übergang von zugesetztem Scopoletin in den Hauptstromrauch nachzuweisen, wurden drei Versionen von Versuchscigaretten auf Basis des gleichen Cigaretten-Loses wie in Beispiel 1 hergestellt. Dabei wurde auf bekannte Weise der Tabak von 60 Filtercigaretten gemäß Beispiel 1 aus diesen mittels Druckluft ausgeblasen, aufgefangen, gedrittelt, zwei Drittel mit dem Naturstoff aviviert (der Vergleich nur mit Ethanol) und in 60 gleichen Anteilen den ausgeblasenen, in drei Lose unterteilten 3 x 20 Filterhülsen mittels einer handelsüblichen Tabakstopfmaschine für Filtercigarettenhülsen wieder zugefügt, wobei sich allerdings das Stranggewicht der derart gefertigten Filtercigaretten geringfügig verringerte. Dabei wurde die Konzentration an Scopoletin des Tabaks durch Auf sprühen einer ethanolischen Lösung von Scopoletin auf den Cigaretten-Tabak von ursprünglich 330 ppm auf 630 ppm bzw. 5.330 ppm erhöht. Die hergestellten Cigaretten wurden wie in Beispiel 1 beschrieben abgeraucht, wobei das aufgefangene Rauchkondensat in Methanol gelöst wurde. Die Filterhülsen-Design Daten entsprachen denen des Beispiels 1, das Stranggewicht verringerte sich auf 930 ± 20 mg, die abgerauchte Tabakmenge lag bei 785 mg. Scopoletin (7-hydroxy-6-methoxycoumarin) with a melting point of 205 ° C, without boiling point, is a natural plant ingredient in Virginia tobacco in a concentration of about Contain 300 ppm. To prevent the addition of scopoletin to to detect the mainstream smoke, three versions of Trial cigarettes based on the same lot of cigarettes as prepared in Example 1. The was in a known manner Tobacco from 60 filter cigarettes according to Example 1 using these Blown out compressed air, collected, divided into thirds, two thirds advanced with the natural product (comparison only with ethanol) and in 60 equal parts the blown out, in three lots divided 3 x 20 filter sleeves using a commercially available Tobacco tamping machine for filter cigarette tubes added again, however, the strand weight of the so manufactured Filter cigarettes slightly reduced. The concentration to scopoletin of tobacco by spraying on an ethanolic Solution of Scopoletin on the original cigarette tobacco Increased 330 ppm to 630 ppm and 5.330 ppm. The manufactured Cigarettes were smoked as described in Example 1, whereby the collected smoke condensate is dissolved in methanol has been. The filter sleeve design data corresponded to that of the example 1, the strand weight decreased to 930 ± 20 mg, the amount of tobacco smoked was 785 mg.
Die analytische Bestimmung des Scopoletins erfolgte mittels HPLC
unter folgenden Bedingungen:
In der folgenden Tabelle 5 sind die erhaltenen Versuchsergebnisse
zusammengestellt.
Die Versuche mit Scopoletin, als Vertreter der nichtflüchtigen antimutagen wirkenden Substanzen, zeigen, daß die Beaufschlagung des Tabaks mit 300 bzw. 5.000 ppm zu einem Stoffübergang von 9,6 resp. 6,2% in den Hauptstromrauch geführt hat.The experiments with scopoletin, as a representative of the non-volatile antimutagenic substances, show that the exposure of the tobacco with 300 or 5,000 ppm to a mass transfer of 9.6 resp. 6.2% in the main electricity smoke.
Die Ergebnisse des nachfolgend beschriebenen Versuches zeigen, daß die in den Rauch übergehenden antioxidativ wirksamen Substanzen aus Abmischungen von Schnittabak mit Nelken resp. Zimtstangen, sowie die Beaufschlagung mit reinem Eugenol, die mutagene Wirkung so entstandenen Rauchkondensates vermindern.The results of the experiment described below show that the antioxidative substances that pass into the smoke from blends of cut tobacco with cloves respectively. Cinnamon sticks, and the application of pure eugenol, the mutagenic Reduce the effect of smoke condensate.
Es wurden fünf Versionen Filtercigaretten, die sich bei gleicher
Tabak-Basismischung in der Zusammensetzung der Endmischung gemäß
Tabelle 6 unterschieden, in gleicher Ausstattung und gleichem
Cigarettengewicht (940 mg) hergestellt. Die eingesetzten Nelken
bzw. Zimtstangen wurden vor dein Mischen mit Tabak mit Dampf
aufgefeuchtet, gewalzt und geschnitten. Die Aufgabe des Eugenols
erfolgte in 20%iger ethanolischer Lösung, wobei der Alkohol nach
der Behandlung quantitativ verdunstet wurde.
Die Versuchs cigaretten wurden unter Normbedingungen abgeraucht (siehe Beispiel 1). Die daraus resultierenden Rauchkondensatlösungen wurden mit dem Ames-Test gemäß Beispiel 2 untersucht, und zwar in der Ausführungsform "mit S9-Aktivierung". Zur Bewertung der Mutagenität wurden gleiche Rauchkondensatmengen eingesetzt und die Ergebnisse auf den unbehandelten Vergleich = 100 % bezogen.The experimental cigarettes were smoked under standard conditions (see example 1). The resulting smoke condensate solutions were examined with the Ames test according to Example 2, and in the embodiment "with S9 activation". For evaluation equal amounts of smoke condensate were used for the mutagenicity and the results based on the untreated comparison = 100%.
In Figur 7 sind die Versuchsergebnisse graphisch dargestellt.
Die Mutagenität des Rauchkondensates der Mischung 1 wurde auf
55,5 % der Wirkung des Vergleichs vermindert, was sich mit der
in den Nelken enthaltenen Eugenolmenge erklären läßt. Die eingesetzten
Nelken hatten einen Eugenolgehalt von 17,0 %. Im Gegensatz
dazu kann die überraschende Verminderung der Mutagenität
des Rauchkondensates der Mischung 2 auf 65,3 % nicht allein mit
den enthaltenen Mengen an Zimtaldehyd und Eugenol erklärt werden.The test results are shown graphically in FIG.
The mutagenicity of the smoke condensate of mixture 1 was increased
55.5% of the effect of the comparison diminished, which corresponds to the
explain the amount of eugenol contained in the cloves. The used
Carnations had an eugenic content of 17.0%. In contrast
this can be accompanied by the surprising reduction in mutagenicity
of the smoke condensate of
Claims (19)
- A smokable product made from tobacco and/or another smokable material, the tobacco and/or the smokable material containing an addition of natural substances with an antioxidant action and/or synthetic products thereof with an identical nature, characterised in that the addition is a combination of(a) vitamins having an antioxidant action, selected from the group consisting of retinol, α-tocopherol, their precursors and/or derivatives, and(b) other natural substances of plant origin having anti-mutagenic and aromatising properties, selected from the group consisting of ethyl vanillin, cinnamon aldehyde, aniseed aldehyde, eugenol, limonene, cinnamon and cinnamon extract.
- A smokable product according to Claim 1,
characterised in that it contains up to 25 % by weight of the natural substances with an antioxidant action and/or synthetic products with an identical nature. - A smokable product according to Claim 2,
characterised in that it contains 1 to 5 % by weight of the natural substances having an antioxidant action and/or synthetic products with an identical nature. - A smokable product according to one of Claims 1 to 3,
characterised in that it is a cigarette with or without a filter. - A smokable product according to one of Claims 1 to 3,
characterised in that it is a cigarillo with or without a filter. - A smokable product according to one of Claims 1 to 3,
characterised in that it is a tobacco cartridge with or without a filter. - A smokable product according to one of Claims 1 to 3,
characterised in that it is smoking tobacco in the form of fine cut or pipe tobacco. - A smokable product according to one of Claims 4 to 6,
characterised in that the filter contains up to 50 % by weight of the natural substances having an antioxidant action and/or synthetic products with an identical nature according to Claim 1. - A smokable product according to Claim 8,
characterised in that the filter contains 1 to 20 % by weight of the natural substances having an antioxidant action and/or synthetic products with an identical nature according to Claim 1. - A smokable product according to Claim 4,
characterised in that the cigarette paper contains up to 50 % by weight of the natural substances having an antioxidant action and/or synthetic products with an identical nature according to Claim 1. - A smokable product according to one of the preceding Claims,
characterised in that the smokable base material are mixtures of leaf tobaccos or leaf tobacco and foil tobacco. - A smokable product according to one of the preceding Claims,
characterised in that the smokable material contains up to 25 % by weight of the natural substances having an antioxidant action and/or synthetic products with an identical nature according to Claim 1. - A smokable product according to one of the preceding Claims,
characterised in that the smokable material is a tobacco-free mixture of plant material, which is derived from coltsfoot, peppermint, stinging nettle, broad-leaved plantain, spearmint, lavender, thyme, sweet or sour cherry leaves, knotweed leaves, rose leaves, pimento leaves or cinnamon bark. - A smokable product according to Claim 13,
characterised in that the smokable material is derived from cinnamon bark. - A smokable product according to Claims 11 to 14,
characterised in that the smokable material is a combination of tobacco mixture and tobacco-free mixture. - A process for the manufacture of a smokable product according to Claims 1 to 15 in a manner known per se, in which the natural substances having an antioxidant action and/or their synthetic products with an identical nature are incorporated or revived into the tobacco and/or another smokable material in a manner known per se.
- A process according to Claim 16,
characterised in that the smokable material comprises a tobacco-free mixture consisting of plant material, wrappers, supporting materials, seam adhesive and the like. - A process according to Claims 16 and 17,
characterised in that the smokable product is a cigarette, a cigarillo or a tobacco cartridge with filter, in the filter of which up to 50 % by weight of the natural substances having an antioxidant action and/or synthetic products with an identical nature according to Claim 1 are incorporated or revived. - A process according to Claim 18,
characterised in that the substances usually used as hardeners for the cellulose acetate fibres forming the subsequent filter are particularly or completely replaced by the natural substances having an antioxidant action according to Claim 1 and/or their synthetic products with an identical nature.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI9530458T SI0756461T1 (en) | 1994-04-19 | 1995-04-18 | Tobacco products, or substances similar to such products, containing natural substances with anti-oxidant properties, and process for producing the same |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4416101A DE4416101C2 (en) | 1994-04-19 | 1994-04-19 | Tobacco products or tobacco products similar goods with natural substances having an antioxidative effect and process for producing the same |
| DE4416101 | 1994-04-19 | ||
| PCT/EP1995/001452 WO1995028098A1 (en) | 1994-04-19 | 1995-04-18 | Tobacco products, or substances similar to such products, containing natural substances with anti-oxidant properties, and process for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0756461A1 EP0756461A1 (en) | 1997-02-05 |
| EP0756461B1 true EP0756461B1 (en) | 2000-11-02 |
Family
ID=6517522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP95917934A Expired - Lifetime EP0756461B1 (en) | 1994-04-19 | 1995-04-18 | Tobacco products, or substances similar to such products, containing natural substances with anti-oxidant properties, and process for producing the same |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5944026A (en) |
| EP (1) | EP0756461B1 (en) |
| JP (1) | JPH10503082A (en) |
| KR (1) | KR100357665B1 (en) |
| CN (1) | CN1148324A (en) |
| AT (1) | ATE197226T1 (en) |
| BG (1) | BG63420B1 (en) |
| CA (1) | CA2184592A1 (en) |
| CZ (1) | CZ294496A3 (en) |
| DE (2) | DE4416101C2 (en) |
| DK (1) | DK0756461T3 (en) |
| EE (1) | EE9600149A (en) |
| ES (1) | ES2151598T3 (en) |
| GR (1) | GR3035240T3 (en) |
| HU (1) | HUT76247A (en) |
| LV (1) | LV11721B (en) |
| MD (1) | MD1976B2 (en) |
| PL (1) | PL177413B1 (en) |
| PT (1) | PT756461E (en) |
| RO (1) | RO117888B1 (en) |
| RU (1) | RU2142729C1 (en) |
| SI (1) | SI0756461T1 (en) |
| SK (1) | SK120496A3 (en) |
| TW (1) | TW272117B (en) |
| UA (1) | UA45336C2 (en) |
| WO (1) | WO1995028098A1 (en) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4416101C2 (en) * | 1994-04-19 | 1997-06-12 | Reemtsma H F & Ph | Tobacco products or tobacco products similar goods with natural substances having an antioxidative effect and process for producing the same |
| DE19541873A1 (en) * | 1995-11-09 | 1997-05-15 | Rhodia Ag Rhone Poulenc | Filter cigarette |
| JPH1192410A (en) * | 1997-09-25 | 1999-04-06 | Naohiko Sato | Antioxidatively active substance |
| US6082370A (en) * | 1998-02-09 | 2000-07-04 | Rousseau Research, Inc. | Cigarette with dry powered Vitamin E |
| CZ20002901A3 (en) * | 1998-02-09 | 2001-08-15 | Rousseau Research, Inc. | Tobacco articles containing vitamin E |
| US6615842B1 (en) | 1998-02-13 | 2003-09-09 | Cerami Consulting Corp. | Methods for removing nucleophilic toxins from tobacco smoke |
| EA200100917A1 (en) * | 1999-02-26 | 2002-08-29 | Х.Ф. Унд Ф.Ф. Реемтсма Гмбх | SMOKING PRODUCT |
| GB0014465D0 (en) * | 2000-06-14 | 2000-08-09 | British American Tobacco Co | Improvements relating to smokable filler material |
| EP1309253B1 (en) * | 2000-06-26 | 2007-05-23 | Cerami Consulting Corporation | Methods and devices for removing nucleophilic toxins from tobacco and tobacco smoke |
| US20050138910A1 (en) * | 2000-10-16 | 2005-06-30 | Peter Rohdewald | Air filter with scavenging effect on free radicals in gaseous phase and its method of preparation |
| US7325548B2 (en) * | 2001-04-09 | 2008-02-05 | George Frederick Enslin | Smoker's requisite |
| KR20030004562A (en) * | 2001-07-05 | 2003-01-15 | 정진남 | Cigarette |
| EP1419706A1 (en) * | 2001-08-02 | 2004-05-19 | Japan Tobacco Inc. | Filter for cigarette |
| US6953040B2 (en) * | 2001-09-28 | 2005-10-11 | U.S. Smokeless Tobacco Company | Tobacco mint plant material product |
| RU2226399C2 (en) * | 2002-01-08 | 2004-04-10 | Воробьев Евгений Александрович | Preparation for losing the habit for smoking |
| RU2197158C1 (en) * | 2002-01-16 | 2003-01-27 | Поддубный Игорь Евгеньевич | Smoking composition for low-toxicity cigarettes and composition preparing method |
| HUP0201257A2 (en) * | 2002-04-17 | 2004-05-28 | Péter Rozim | Filter for filter-tipped cigarette |
| RU2235543C1 (en) * | 2003-01-28 | 2004-09-10 | Государственное учреждение Научно-исследовательский институт по изысканию новых антибиотиков им. Г.Ф. Гаузе | Method for increasing inspecific body resistance |
| RU2256387C2 (en) * | 2003-05-19 | 2005-07-20 | Шамов Виталий Борисович | Smoking filling material |
| US20040255965A1 (en) | 2003-06-17 | 2004-12-23 | R. J. Reynolds Tobacco Company | Reconstituted tobaccos containing additive materials |
| EP1681949A2 (en) * | 2003-11-03 | 2006-07-26 | U.S. Smokeless Tobacco Company | Flavored smokeless tabacco and methods of making |
| RU2355264C1 (en) | 2005-03-02 | 2009-05-20 | Джапан Тобакко Инк. | Cigarette production machine |
| ATE446022T1 (en) * | 2005-07-08 | 2009-11-15 | Ioto Internat Ind E Com De Pro | DEVICE FOR REPROCESSING POWDERS OF VEGETABLE ORIGIN |
| US7323476B2 (en) * | 2006-03-03 | 2008-01-29 | Savipu Pharmaceuticals | Myriceric acid derivatives for the treatment of cancer, cardiovascular and inflammatory diseases |
| US7795306B2 (en) * | 2006-03-03 | 2010-09-14 | Inderjit Kumar Dev | Triterpene derivatives for the treatment of cancer and inflammatory disease by inhibition of NF-κB |
| US20070207989A1 (en) * | 2006-03-03 | 2007-09-06 | Savipu Pharmaceuticals | Diterpene derivatives for the treatment of cardiovascular, cancer and inflammatory diseases |
| RU2306780C1 (en) * | 2006-03-13 | 2007-09-27 | Олег Иванович Квасенков | Method for producing of aromatized tobacco vein |
| RU2306782C1 (en) * | 2006-03-14 | 2007-09-27 | Олег Иванович Квасенков | Method for producing of puffed tobacco vein |
| RU2306781C1 (en) * | 2006-03-14 | 2007-09-27 | Олег Иванович Квасенков | Method for producing of expanded tobacco vein |
| RU2306783C1 (en) * | 2006-03-14 | 2007-09-27 | Олег Иванович Квасенков | Method for producing of puffed tobacco vein |
| RU2306806C1 (en) * | 2006-03-15 | 2007-09-27 | Олег Иванович Квасенков | Method for producing of aromatized expanded tobacco vein |
| RU2306802C1 (en) * | 2006-03-15 | 2007-09-27 | Олег Иванович Квасенков | Method for producing of puffed tobacco vein |
| RU2306796C1 (en) * | 2006-03-16 | 2007-09-27 | Олег Иванович Квасенков | Method for producing of expanded tobacco vein |
| RU2307556C1 (en) * | 2006-03-16 | 2007-10-10 | Олег Иванович Квасенков | Method for producing of puffed tobacco stem |
| RU2306797C1 (en) * | 2006-03-16 | 2007-09-27 | Олег Иванович Квасенков | Method for producing of aromatized expanded tobacco vein |
| RU2306807C1 (en) * | 2006-03-16 | 2007-09-27 | Олег Иванович Квасенков | Method for producing of puffed tobacco vein |
| RU2309644C1 (en) * | 2006-03-30 | 2007-11-10 | Олег Иванович Квасенков | Method for producing of expanded tobacco |
| US20070243273A1 (en) * | 2006-04-12 | 2007-10-18 | Savipu Pharmaceuticals | Reduction of the Deleterious Effects of Tobacco Smoking |
| US20080017207A1 (en) * | 2006-07-18 | 2008-01-24 | Savipu Pharmaceuticals | Reduction of the Deleterious Effects of Tobacco Smoking by the Induction of Phase 2 Enzymes by Nerf2 |
| RU2328185C1 (en) * | 2006-12-11 | 2008-07-10 | Олег Иванович Квасенков | Method for manufacturing light kreteks |
| RU2328182C1 (en) * | 2006-12-11 | 2008-07-10 | Олег Иванович Квасенков | Method for production of lightened kreteks |
| RU2328181C1 (en) * | 2006-12-11 | 2008-07-10 | Олег Иванович Квасенков | Method for manufacturing lightened kreteks |
| RU2328180C1 (en) * | 2006-12-11 | 2008-07-10 | Олег Иванович Квасенков | Method for manufacturing lightened kreteks |
| RU2328178C1 (en) * | 2006-12-11 | 2008-07-10 | Олег Иванович Квасенков | Method for producing kreteks |
| RU2328179C1 (en) * | 2006-12-11 | 2008-07-10 | Олег Иванович Квасенков | Method for manufacturing kreteks having low tar and nicotine content |
| RU2328177C1 (en) * | 2006-12-12 | 2008-07-10 | Олег Иванович Квасенков | Method for producing lightened kreteks |
| RU2328191C1 (en) * | 2006-12-12 | 2008-07-10 | Олег Иванович Квасенков | Method for producing light kreteks |
| RU2326572C1 (en) * | 2006-12-12 | 2008-06-20 | Олег Иванович Квасенков | Method for producing kreteks |
| RU2328183C1 (en) * | 2006-12-12 | 2008-07-10 | Олег Иванович Квасенков | Method for manufacturing lightened kreteks |
| RU2326569C1 (en) * | 2006-12-12 | 2008-06-20 | Олег Иванович Квасенков | Method for manufacturing kreteks |
| RU2326560C1 (en) * | 2006-12-13 | 2008-06-20 | Олег Иванович Квасенков | Method for manufacturing kreteks |
| US20080187608A1 (en) * | 2007-02-05 | 2008-08-07 | Savipu Pharmaceuticals | Enriched fractions from clary sage for the treatment of cancer, cardiovascular and inflammatory diseases |
| US20090022821A1 (en) * | 2007-07-17 | 2009-01-22 | Inderjit Kumar Dev | Compositions from wax myrtle for the treatment of cancer, cardiovascular and inflammatory diseases |
| KR100903951B1 (en) | 2007-07-19 | 2009-06-25 | 주식회사 케이티앤지 | Cigarette filter containing ascorbic acid derivative for free radical removal in mainstream smoke |
| RU2380992C1 (en) * | 2008-08-29 | 2010-02-10 | Тагир Эюб Оглы Агаев | Method for preparation of smoking composition |
| RU2380991C1 (en) * | 2008-08-29 | 2010-02-10 | Тагир Эюб Оглы Агаев | Smoking composition |
| RU2403832C1 (en) * | 2009-08-10 | 2010-11-20 | Общество с ограниченной ответственностью Торгово-Промышленное Предприятие "Столичное" | Method for production of smoking composition for calean |
| PH12012500568A1 (en) | 2009-10-09 | 2012-10-22 | Philip Morris Products Sa | Combination treatment of tobacco extract using antioxidants and antioxidant scavengers |
| CN102495162B (en) * | 2011-11-16 | 2013-11-20 | 中国烟草总公司郑州烟草研究院 | Method for determining content of eugenol in formulated cut tobacco |
| CN102499437A (en) * | 2011-11-20 | 2012-06-20 | 红云红河烟草(集团)有限责任公司 | Lavender-doped tobacco baking and flavoring method |
| KR101475611B1 (en) * | 2013-07-01 | 2014-12-22 | 이규서 | Process for Anti-Stress Cigarette of Aromatheraphy by Functional Flavor |
| CN103601710B (en) * | 2013-11-04 | 2015-12-02 | 广东中烟工业有限责任公司 | Coumarin derivatives and its preparation method and application |
| US10470490B2 (en) * | 2014-06-19 | 2019-11-12 | Daicel Corporation | Cigarette filter tow band |
| RU2593073C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2586474C1 (en) * | 2015-03-27 | 2016-06-10 | Олег Иванович Квасенков | Method for production of smoking composition |
| RU2593068C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2586472C1 (en) * | 2015-03-27 | 2016-06-10 | Олег Иванович Квасенков | Method for production of smoking composition |
| RU2583778C1 (en) * | 2015-03-27 | 2016-05-10 | Олег Иванович Квасенков | Method for production of smoking composition |
| RU2593076C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593074C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2584868C1 (en) * | 2015-03-27 | 2016-05-20 | Олег Иванович Квасенков | Method for production of smoking composition |
| RU2593082C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593086C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593072C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593075C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593071C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593083C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593084C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2586477C1 (en) * | 2015-03-27 | 2016-06-10 | Олег Иванович Квасенков | Method for production of smoking composition |
| RU2593085C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2586478C1 (en) * | 2015-03-27 | 2016-06-10 | Олег Иванович Квасенков | Method for production of smoking composition |
| RU2593081C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593070C1 (en) * | 2015-03-27 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2594141C1 (en) * | 2015-04-10 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2586475C1 (en) * | 2015-04-10 | 2016-06-10 | Олег Иванович Квасенков | Method for production of smoking mixture for hookah |
| RU2584856C1 (en) * | 2015-04-10 | 2016-05-20 | Олег Иванович Квасенков | Method for production of smoking mixture for hookah |
| RU2594139C1 (en) * | 2015-04-10 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593077C1 (en) * | 2015-04-10 | 2016-07-27 | Олег Иванович Квасенков | Method for production of smoking mixture for hookah |
| RU2593116C1 (en) * | 2015-04-10 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593078C1 (en) * | 2015-04-10 | 2016-07-27 | Олег Иванович Квасенков | Method for production of smoking mixture for hookah |
| RU2594138C1 (en) * | 2015-04-10 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593134C1 (en) * | 2015-04-10 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593977C1 (en) * | 2015-04-10 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2596101C1 (en) * | 2015-04-10 | 2016-08-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" | Method for production of hookah smoking composition |
| RU2594140C1 (en) * | 2015-04-10 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593118C1 (en) * | 2015-04-10 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593126C1 (en) * | 2015-04-20 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2594133C1 (en) * | 2015-04-20 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593128C1 (en) * | 2015-04-20 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593978C1 (en) * | 2015-04-20 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593120C1 (en) * | 2015-04-20 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593119C1 (en) * | 2015-04-20 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2594132C1 (en) * | 2015-04-20 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593130C1 (en) * | 2015-04-20 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593969C1 (en) * | 2015-04-28 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593123C1 (en) * | 2015-04-28 | 2016-07-27 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2594136C1 (en) * | 2015-04-28 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2594135C1 (en) * | 2015-04-28 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2594137C1 (en) * | 2015-04-28 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2594134C1 (en) * | 2015-04-28 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2596446C1 (en) * | 2015-05-20 | 2016-09-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593974C1 (en) * | 2015-05-20 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2593976C1 (en) * | 2015-05-20 | 2016-08-10 | Олег Иванович Квасенков | Method for production of hookah smoking composition |
| RU2599356C1 (en) * | 2015-05-20 | 2016-10-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" | Method for production of hookah smoking composition |
| CN105394808A (en) * | 2015-12-17 | 2016-03-16 | 立场电子科技发展（上海）有限公司 | Atomization liquid for electronic cigarette |
| WO2018045174A1 (en) * | 2016-08-31 | 2018-03-08 | Baybutt Richard | Composition and use thereof |
| EP3589787A4 (en) * | 2017-03-02 | 2021-01-06 | Iiw Entourage Delivery Systems Ltd | Aromatized and flavored paper products |
| CN107485052A (en) * | 2017-08-09 | 2017-12-19 | 江西中烟工业有限责任公司 | A kind of application of liposoluble vitamin in tobacco mouth rod |
| SG10201903923SA (en) * | 2018-12-31 | 2020-03-30 | Ysq Int Pte Ltd | Apparatus and method for producing a filter element |
| CN118141149A (en) * | 2024-04-15 | 2024-06-07 | 浙江中烟工业有限责任公司 | A heated cigarette core material with clove flavor |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3339558A (en) * | 1966-10-28 | 1967-09-05 | Haskett Barry F | Smoking article and filter therefor containing vitamin a |
| US3861401A (en) * | 1973-03-08 | 1975-01-21 | Theodore S Briskin | Smokable tobacco substitute material and method |
| US3943943A (en) * | 1974-07-09 | 1976-03-16 | Liggett & Myers Incorporated | Cinnamic derivatives as tobacco additives |
| US3940499A (en) * | 1974-09-19 | 1976-02-24 | International Flavors & Fragrances Inc. | Food or flavor containing 2,6,6-trimethyl-1-cyclohexen-1-ylacetaldehyde |
| US4170236A (en) * | 1977-06-16 | 1979-10-09 | International Flavors & Fragrances Inc. | Isobutyl substituted heterocyclic compounds and uses for augmenting or enhancing the organoleptic properties of smoking compositions |
| DE3200305C2 (en) * | 1982-01-08 | 1983-11-17 | B.A.T. Cigaretten-Fabriken Gmbh, 2000 Hamburg | Process for improving the filling capacity of tobacco, in particular tobacco leaf cut |
| US4516590A (en) * | 1982-11-26 | 1985-05-14 | Philip Morris Incorporated | Air-cured bright tobacco filler, blends and smoking articles |
| CH662042A5 (en) * | 1983-07-14 | 1987-09-15 | Baumgartner Papiers Sa | Cigarette endpiece |
| HU192213B (en) * | 1985-04-29 | 1987-05-28 | Pecsi Dohanygyar | Method for producing smoke filter neutralizing the materials injurious the health being in tobacco smoke particularly aldehydes |
| JPS6214772A (en) * | 1985-07-10 | 1987-01-23 | 中島 三夫 | Innoxious tobacco |
| US4727058A (en) * | 1985-09-26 | 1988-02-23 | International Flavors & Fragrances Inc. | Process for preparing natural benzaldehyde and acetaldehyde, natural benzaldehyde and acetaldehyde compositions, products produced thereby and organoleptic utilities therefor |
| IT8717404A0 (en) * | 1987-05-07 | 1987-05-07 | Barbaro Daniele | LOCAL DELIVERY SYSTEM, FOR SMOKERS, OF VITAMIN A (OR OTHER RETINOIDS) HAVING CIGARETTE OR CIGAR SMOKE AS ELUENT (SOLVENT AND VEHICLE). |
| WO1989001301A1 (en) * | 1987-08-13 | 1989-02-23 | C.A. Blockers, Inc. | Tobacco smoking article |
| US5000198A (en) * | 1989-06-13 | 1991-03-19 | Mituo Nakajima | Agent for removing noxious tobacco components |
| JPH03219860A (en) * | 1990-01-25 | 1991-09-27 | Daicel Chem Ind Ltd | Filter for tobacco smoke |
| JPH0523159A (en) * | 1991-07-19 | 1993-02-02 | Kikkoman Corp | Cigarette filter |
| US5308874A (en) * | 1992-06-26 | 1994-05-03 | Vyrex Corporation | Airborne protectants against oxidative tissue damage |
| JPH0662824A (en) * | 1992-08-12 | 1994-03-08 | Kyodo Nyugyo Kk | Method for removing free radical from tobacco smoke |
| DE4244467C2 (en) * | 1992-12-24 | 1996-11-14 | Reemtsma H F & Ph | Cigarette |
| DE4416101C2 (en) * | 1994-04-19 | 1997-06-12 | Reemtsma H F & Ph | Tobacco products or tobacco products similar goods with natural substances having an antioxidative effect and process for producing the same |
-
1994
- 1994-04-19 DE DE4416101A patent/DE4416101C2/en not_active Revoked
-
1995
- 1995-04-18 SI SI9530458T patent/SI0756461T1/en unknown
- 1995-04-18 MD MD96-0320A patent/MD1976B2/en unknown
- 1995-04-18 UA UA96103945A patent/UA45336C2/en unknown
- 1995-04-18 CA CA002184592A patent/CA2184592A1/en not_active Abandoned
- 1995-04-18 TW TW084103810A patent/TW272117B/zh active
- 1995-04-18 CN CN95192648A patent/CN1148324A/en active Pending
- 1995-04-18 EP EP95917934A patent/EP0756461B1/en not_active Expired - Lifetime
- 1995-04-18 PT PT95917934T patent/PT756461E/en unknown
- 1995-04-18 PL PL95316760A patent/PL177413B1/en unknown
- 1995-04-18 SK SK1204-96A patent/SK120496A3/en unknown
- 1995-04-18 KR KR1019960705290A patent/KR100357665B1/en not_active Expired - Fee Related
- 1995-04-18 RO RO96-01987A patent/RO117888B1/en unknown
- 1995-04-18 DK DK95917934T patent/DK0756461T3/en active
- 1995-04-18 ES ES95917934T patent/ES2151598T3/en not_active Expired - Lifetime
- 1995-04-18 DE DE59508825T patent/DE59508825D1/en not_active Expired - Fee Related
- 1995-04-18 JP JP7526734A patent/JPH10503082A/en active Pending
- 1995-04-18 WO PCT/EP1995/001452 patent/WO1995028098A1/en not_active Ceased
- 1995-04-18 CZ CZ962944A patent/CZ294496A3/en unknown
- 1995-04-18 US US08/727,411 patent/US5944026A/en not_active Expired - Fee Related
- 1995-04-18 AT AT95917934T patent/ATE197226T1/en not_active IP Right Cessation
- 1995-04-18 RU RU96121906A patent/RU2142729C1/en active
- 1995-04-18 HU HU9602896A patent/HUT76247A/en unknown
- 1995-04-18 EE EE9600149A patent/EE9600149A/en unknown
-
1996
- 1996-09-04 LV LVP-96-357A patent/LV11721B/en unknown
- 1996-10-18 BG BG100927A patent/BG63420B1/en unknown
-
2001
- 2001-01-15 GR GR20010400056T patent/GR3035240T3/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HU9602896D0 (en) | 1996-12-30 |
| ES2151598T3 (en) | 2001-01-01 |
| UA45336C2 (en) | 2002-04-15 |
| CA2184592A1 (en) | 1995-10-26 |
| BG63420B1 (en) | 2002-01-31 |
| KR100357665B1 (en) | 2003-02-05 |
| WO1995028098A1 (en) | 1995-10-26 |
| DK0756461T3 (en) | 2000-12-18 |
| KR970701507A (en) | 1997-04-12 |
| DE4416101A1 (en) | 1995-10-26 |
| PL316760A1 (en) | 1997-02-03 |
| TW272117B (en) | 1996-03-11 |
| MD1976B2 (en) | 2002-08-31 |
| PT756461E (en) | 2001-04-30 |
| DE59508825D1 (en) | 2000-12-07 |
| HUT76247A (en) | 1997-07-28 |
| CN1148324A (en) | 1997-04-23 |
| CZ294496A3 (en) | 1997-04-16 |
| DE4416101C2 (en) | 1997-06-12 |
| RU2142729C1 (en) | 1999-12-20 |
| SK120496A3 (en) | 1997-03-05 |
| JPH10503082A (en) | 1998-03-24 |
| ATE197226T1 (en) | 2000-11-15 |
| BG100927A (en) | 1997-07-31 |
| LV11721A (en) | 1997-04-20 |
| LV11721B (en) | 1997-12-20 |
| HK1012873A1 (en) | 1999-09-17 |
| RO117888B1 (en) | 2002-09-30 |
| SI0756461T1 (en) | 2001-04-30 |
| US5944026A (en) | 1999-08-31 |
| GR3035240T3 (en) | 2001-04-30 |
| PL177413B1 (en) | 1999-11-30 |
| EE9600149A (en) | 1997-04-15 |
| EP0756461A1 (en) | 1997-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0756461B1 (en) | Tobacco products, or substances similar to such products, containing natural substances with anti-oxidant properties, and process for producing the same | |
| DE69221635T2 (en) | NEW TOBACCO REPLACEMENTS | |
| DE1517242A1 (en) | Filter element | |
| LV12123B (en) | CIGARETE WITH FILTER | |
| EP0069056B1 (en) | Process to aromatise tabacco smoke, cigarette end piece to carry out the process, and use of the process | |
| DE3532618C2 (en) | ||
| DE2246221A1 (en) | SMOKING MATERIAL, PROCESS FOR THE PREPARATION THEREOF AND SMOKING PRODUCTS MANUFACTURED THEREFROM | |
| EP1843670B1 (en) | Filter cigarette | |
| DE69830158T2 (en) | REGULATOR FOR TOBACCO TOUCH AROMA | |
| DE533199C (en) | Process for the production of cigarette paper | |
| DE60034968T2 (en) | METHOD AND DEVICE FOR REMOVING NUCLEOPHILIC TOXINS FROM TOBACCO AND TOBACCO TOUCH | |
| DE19746664A1 (en) | Thin cigarette | |
| DD153571A5 (en) | METHOD FOR THE TREATMENT OF SMOKING TOBACCO FOR THE DETECTION OF POLLUTION IN SMOKE | |
| DE3021668A1 (en) | METHOD FOR THE AROMATIZATION OF TOBACCO SMOKE, CIGARETTE END PIECE FOR CARRYING OUT THE METHOD AND USE OF THE METHOD | |
| DE1517320A1 (en) | Additives for tobacco products | |
| DE2738930A1 (en) | SMOKING OBJECT | |
| DE69202392T2 (en) | Improvements in smoking articles. | |
| DE2256235A1 (en) | METHOD OF TREATING TOBACCO | |
| DE19957487A1 (en) | Smokable items | |
| DE2120913A1 (en) | Process for the production of homogenized tobacco material | |
| DE1517297C (en) | Smoke filters for tobacco products | |
| DE2313996C3 (en) | Water-soluble, easily absorbable snuff and process for its manufacture | |
| DE2023277A1 (en) | Filters for tobacco smoke, in particular material for the manufacture of these filters | |
| DE1004986B (en) | Filter body for detoxifying tobacco smoke | |
| DE1792124A1 (en) | Process for influencing the taste of tobacco or tobacco products by adding substances that flavor the tobacco smoke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19961025 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: LT PAYMENT 961025;SI PAYMENT 961025 |
|
| 17Q | First examination report despatched |
Effective date: 19970313 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: H.F. & PH.F. REEMTSMA GMBH |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: LT PAYMENT 19961025;SI PAYMENT 19961025 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20001102 |
|
| REF | Corresponds to: |
Ref document number: 197226 Country of ref document: AT Date of ref document: 20001115 Kind code of ref document: T |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: PATENTANWALTSBUREAU R. A. MASPOLI Ref country code: CH Ref legal event code: EP |
|
| ITF | It: translation for a ep patent filed | ||
| GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20001102 |
|
| REF | Corresponds to: |
Ref document number: 59508825 Country of ref document: DE Date of ref document: 20001207 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: GERMAN |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
| ET | Fr: translation filed | ||
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2151598 Country of ref document: ES Kind code of ref document: T3 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010202 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010418 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010430 |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20010122 |
|
| PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
| PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
| 26 | Opposition filed |
Opponent name: BRITISH AMERICAN TABACCO (GERMANY) GMBH Effective date: 20010712 |
|
| PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
| NLR1 | Nl: opposition has been filed with the epo |
Opponent name: BRITISH AMERICAN TABACCO (GERMANY) GMBH |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
| PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
| PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20020318 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20020321 Year of fee payment: 8 Ref country code: AT Payment date: 20020321 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20020325 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20020328 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20020405 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20020408 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20020409 Year of fee payment: 8 |
|
| RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: REEMTSMA CIGARETTENFABRIKEN GMBH |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20020426 Year of fee payment: 8 Ref country code: CH Payment date: 20020426 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20020619 Year of fee payment: 8 |
|
| NLT2 | Nl: modifications (of names), taken from the european patent patent bulletin |
Owner name: REEMTSMA CIGARETTENFABRIKEN GMBH |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Free format text: H.F. & PH.F. REEMTSMA GMBH TRANSFER- REEMTSMA CIGARETTENFABRIKEN GMBH Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE |
|
| NLS | Nl: assignments of ep-patents |
Owner name: REEMTSMA CIGARETTENFABRIKEN GMBH |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Free format text: REEMTSMA CIGARETTENFABRIKEN GMBH DE Effective date: 20020808 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030418 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030418 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030419 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030430 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030430 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030430 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030430 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
| BERE | Be: lapsed |
Owner name: *REEMTSMA CIGARETTENFABRIKEN G.M.B.H. Effective date: 20030430 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031031 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031101 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031101 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031104 |
|
| NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20031101 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20030418 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| LTLA | Lt: lapse of european patent or patent extension |
Effective date: 20030418 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031231 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20031031 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20030419 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050418 |
|
| PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
| R26 | Opposition filed (corrected) |
Opponent name: BRITISH AMERICAN TABACCO (GERMANY) GMBH Effective date: 20010712 |
|
| PLBD | Termination of opposition procedure: decision despatched |
Free format text: ORIGINAL CODE: EPIDOSNOPC1 |
|
| PLBM | Termination of opposition procedure: date of legal effect published |
Free format text: ORIGINAL CODE: 0009276 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: OPPOSITION PROCEDURE CLOSED |
|
| 27C | Opposition proceedings terminated |
Effective date: 20071126 |